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Abstract 
In recent years, cancer treatment strategies have moved towards personalized approaches, 
specifically tailoring cancer treatments on a single-patient basis using molecular profiles from 
the patients’ tumor genomes. Knowledge of a patient’s molecular profile can be used to 1) 
identify the disease mechanisms and underlying cause of a single patient’s cancer, 2) assign 
patients into treatment groups based on the molecular prognosis, and 3) recommend potential 
treatments for individual patients based on the patient’s molecular signature data. However, the 
bottleneck of the personalized medicine approach lies in the challenge of translating the vast 
amount of sequencing data to meaningful clinical insights.  
This dissertation explores several computational methods that utilize molecular signature data to 
understand disease mechanisms of cancer, categorize patients into biologically relevant subtypes, 
and recommend drug treatments to patients. In the dissertation, we present a method, DawnRank, 
a patient-specific method that determines the potential driving genomic alterations (the drivers)
of cancer. We expand on DawnRank’s capabilities by using the DawnRank scores in key driver 
mutations and copy number variants (CNVs) to identify breast cancer subtypes. We found 5 
alternative subtypes based on potentially clinically relevant driver genes, each with unique 
defining target features and pathways. These subtypes correspond to and build upon our previous 
knowledge of breast cancer subtypes. 
We also identify disease mechanisms in identifying key novel cancer pathways in which driver 
genes interact. We developed a method, C3, which pinpoints patterns of cancer mutations in a 
pathway context from a patient population to detect novel cancer pathways that consist of 
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significant driver genes. C3 improves on current methods in driver pathway detection both on a 
technical aspect and a results-oriented aspect. C3 can detect larger and more consistent pathways 
than previous methods as well as discovering more biologically relevant drivers. Finally, we 
address the issue of drug recommendation in the wake of molecular signature data. We develop a 
method, Scattershot, which combines genomic information along with biological insights on 
cancer disease mechanisms to predict drug response and prioritize drug treatments. Scattershot 
outperforms previous methods in predicting drug response and Scattershot recommends drugs to 
cancer patients that are in line with the actual drugs prescribed by the physician. 
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 Chapter 1: Overview 
Cancer is a disease of the genome that is the second-leading cause of death in the United States 
[1]. Although a “cure” for cancer is a top priority goal for medicine and society alike, cancer is 
notoriously difficult to treat due to the vast amount of genetic diversity and heterogeneity among 
tumors [2], [3]. Tumor heterogeneity is the observation that tumors present distinct 
morphological and phenotypic profiles, and can occur both between two different tumors or even 
within the same tumor [4]. Tumor heterogeneity can be explained by the clonal evolution model 
of cancer, in which tumorigenesis occurs when a genomic alteration (a driver) in a cell improves 
a cell’s fitness, allowing it to outcompete in its environment, divide and grow eventually leading 
to tumorigenesis with the cells of the tumor sharing a common ancestor [5]. Because the driver 
occurs at the molecular level, understanding the human genome  and molecular signature 
information is a crucial tool in combatting cancer [6].  
The ability to utilize vast amounts of molecular signature data has been made possible in the 
recent years. Advances in the scope and reduction in the cost of next-generation sequencing 
technologies have provided us with an opportunity to better characterize the molecular signatures 
of human cancers. Information from sequencing can be used  to identify perturbations between 
cancer cells and normal cells that contribute to tumorigenesis on a single-patient basis, which can 
be used to classify a patient’s cancer as well as recommend potential life-saving cancer 
treatment. The single-patient precision of NGS data paves the way for personalized treatment 
strategies in cancer [7]. The ultimate goal of personalized medicine is to integrate genomic 
information with traditional treatment methods (the patient interview, laboratory testing, and 
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socioeconomic and environment factors) to provide a treatment plan that is tailored to a single 
patient, revolutionizing the way cancer care is conducted [7], [8]. 
Although the prospects of a personalized medicine are promising, the challenges of applying the 
genomic information obtained from the lab bench to the bedside are substantial [9]. Three of the 
most prominent challenges in realizing the dream of personalized medicine to the clinic are: (1) 
improving our understanding cancer development and progression by identifying the drivers  of 
cancer [10], [11]; (2) applying our understanding of the genetic basis of cancer to better improve 
diagnostic capabilities [12]; (3) integrating genomic and diagnostic information to ultimately 
select and prioritize effective treatments for cancer patients [13]. The sheer volume of complex, 
multidimensional data that represents the cancer genomic profiles makes it difficult to analyze 
such molecular signature data [14]. Therefore, new computational and statistical methods are 
needed to model tumor mechanisms, diagnostic subgroups, and treatment suggestions. The 
objective of this dissertation is to develop new computational methods that identify important 
genomic alterations related to tumor mechanisms, comprehensively stratify patient subgroups, 
and effectively recommend drugs for personalized cancer medicine. 
1.1 Personalized approaches in driver identification in cancer 
A key question in cancer genomics is focused on identifying the drivers and the driving 
mechanisms behind the important tumorigenesis pathways related to tumor development and 
progression. A driver is considered to be a genomic alteration such as a mutation or a copy 
number change that significantly increases the fitness of the tumor. The functionality and driving 
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pathways of these alterations may vary. Some hallmark examples include constant response to 
growth signals, no response to anti-growth or apoptosis signals, improved replication potential 
with telomerase, sustained angiogenesis, and factors that promote invasion and metastasis [10]. 
Although the alteration rate is high in many cancer cells, only a small number of mutations will 
lead to tumorigenesis. A key challenge lies in distinguishing “driver” mutations, which 
contribute to tumorigenesis, from functionally neutral “passenger” mutations [15]. The most 
basic approach is to categorize mutations based on recurrence, i.e., the most commonly occurring 
mutations are more likely to be drivers [16], [17], or by comparing mutation rates in individual 
genes based on an empirically derived background mutation rate, such as MutSig [18] and 
MuSiC [19]. Machine learning-based approaches use existing knowledge to help identify drivers. 
For example, CHASM utilizes random forest to classify driver mutations using alterations 
trained from known cancer-causing somatic missense mutations [20] and CONEXIC was 
developed to integrate copy number change and gene expression data to identify potential driver 
genes located in regions that are amplified or deleted in tumors [21]. One very promising class of 
driver detection methods models the interaction a driver might have with associated genes in a 
cancer pathway. Network and pathway-based approaches are one of the most promising methods 
to understand drivers due to their ability to model gene-gene interactions by aggregating small 
effect sizes from individual genes. Examples of network-based driver models include 
PARADIGM-Shift [22], which was developed to utilize pathway-level information along with 
other features (such as expression, methylation, copy number) to infer gain and loss of function 
for mutations; DriverNet [23], which classifies driver mutations as mutations that propagate 
outlying downstream differential expression in the transcriptional regulatory network [23]; and 
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MAXDRIVER, [24] which was proposed to identify driver genes by integrating multiple omics 
data and heterogeneous networks. Our method DawnRank, addresses several of the shortcomings 
of previous methods by providing a truly patient-specific model that does not require population-
level information to make an inference on driver genes. Since DawnRank, multiple new 
ensemble methods have been developed to build consensus drivers that are found by multiple 
types of previously-established methods, including DawnRank. Ensemble methods combine 
insights from recurrence-based information, sequence information, and network information. 
Two recent ensemble methods: EC [25] and MADGiC [26] incorporate this information in a 
machine learning framework to predict drivers. DriverDBv2 [27] is an ensemble method that 
detects drivers from multiple established sources, including results from in DriverNet and 
DawnRank. 
Driver identification software has contributed tremendously to our understanding of how 
alterations in genes may impact cancer. However, the narrative of tumorigenesis does not 
necessarily begin and end with a single alteration in a driver gene. An altered gene may have 
many downstream effects, leading to effects on several pathways that drive cancer [28]. 
Discovery of driver pathways provides insight on how mechanisms of tumorigenesis. Several 
methods have been proposed to model potential driver subnetworks and pathways. One method, 
MEMo [29], found closely related driver groups, called modules, that contribute to 
tumorigenesis using principles of mutual exclusivity. The mutual exclusivity in cancer pathways 
is supported by the observations in which one mutated gene suffices to perturb the function of its 
corresponding pathway. Multiple mutations require significantly higher energy investments on 
the part of cancer cells, and are hence selected against. Zhang et al. [30]  expanded the ideas 
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behind the concept of MEMo with iMCMC, and provided a framework to integrate mutation 
data, copy number, and expression information into cancer network weights which they used to 
identify modules. Dendrix [31] was developed to identify potential driver subnetworks using 
mutual exclusivity and coverage over a patient cohort, without relying on known network 
information. It has the potential to facilitate the discovery of new modules. MDPFinder [32] 
expanded on the overall framework of Dendrix by incorporating gene expression information to 
ensure that genes in discovered mutually exclusive pathways were also co-expressed. Multi-
Dendrix [33] and CoMDP [34] address the limitations of Dendrix and MDPFinder, respectively, 
by allowing their algorithms to find multiple co-occurring modules. More recently, CoMEt [35] 
was proposed to address an inherent bias in Dendrix and Multi-Dendrix that resulted in high 
frequency mutations being significantly more likely to be included in mutually exclusive 
modules. The previous methods are not without limitations. The most prominent limitations are 
the size of the modules and the inability to integrate biological insights such as gene expression 
and gene network interaction in determining driver pathways. Even the most recent method, 
CoMEt cannot efficiently identify modules consisting of more than 10 genes. Incorporation of 
biological insights and the ability to identify expansive functional pathways in cancer are needed 
to improve our understanding of the driving pathways in cancer.  
 
1.2 Personalized approaches to discovering diagnostic cancer subgroups 
 
One of the most useful diagnostic tools in cancer care is the identification of clinically relevant 
patient subgroups. These molecular subgroups, or subtypes, account for tumor heterogeneity by 
stratifying patients with different prognoses, variable first sites of metastasis, differential 
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response to targeted therapeutics, and different rates of survival [36]. The end goal of subtyping 
is to divide patients into strata that will likely respond to tailored cancer treatments. Molecular 
subtypes in breast cancer have been crucial to our understanding in both the clinical features and 
treatments in cancer. Subtypes from both DNA/RNAseq and Microarray data serve as prognostic 
markers that can be used to both predict survival times, relapse times, and other clinical features 
as well as define genetic markers that can serve as therapeutic drug targets [37]. 
 
Breast Cancer (BRCA) has one of the most well-studied molecular subtypes  [38]. The earliest 
molecular subtyping for BRCA used the major hormone receptors in the tumor: Estrogen 
Receptor (ER) and  Progesterone (PR), and the growth factor receptor, Her2 (Her2) [39]. By 
testing for the receptor presence in these three subtypes, clinicians prescribe treatments that 
selectively target these receptors and its corresponding signaling pathway. Nevertheless, 18% of 
BRCA patients do not test positive for any of the three receptors. These patients, called Triple 
Negative Breast Cancer (TNBC) patients, are associated with poor prognosis, poor survival, and 
poor response to traditional BRCA therapeutics due to lack of available drug receptor targets 
[40], [41]. 
 
The advent of next-generation sequencing has made it possible to categorize BRCA subtypes 
through genomic and molecular signature data with the hope to finding new genomic markers 
that guide novel drug development, especially for the sorely needed TNBC patients. The most 
prominent of these methods is PAM50 [36], [42]. PAM50 illustrates a list of fifty gene markers 
whose gene expression serves as features in a median-centered hierarchical clustering, which 
ended up with five major BRCA subtypes: “Luminal A”, “Luminal B”, “Her2”, “Basal”, and 
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“Normal-like”.  In addition to the PAM50 subtypes, the authors of the Molecular Taxonomy in 
Breast Cancer International Consortium (METABRIC) found that the PAM50 “Luminal A” and 
“Luminal B” subtypes could be further divided in significant subtypes using Item Cluster 
Analysis (iClust) [43]. METABRIC found 10 significant BRCA subtypes. The METABRIC 
clusters further break down several of the original PAM50 clusters, especially differentiating 
several types of Luminal A and Her2 clusters. Other methods have defined BRCA subtypes 
using other types of method such as The Cancer Genome Atlas’s (TCGA) BRCA landmark 
paper which found five significant clusters using copy number calls through a Non-Negative 
Matrix Factorization (NMF) [44]. This model used copy number calls exclusively with no gene 
filter and no incorporation of others molecular signature information such as gene expression. 
One promising new approach in BRCA subtype detection lies in using driver genes as features to 
further stratify BRCA subtypes. Specific mutations and copy number alterations have used as 
factors to identify specific subgroups within Luminal breast cancers [45], and one potential 
future direction in breast cancer research lies in using driver genes as features in identifying 
alternate BRCA subtypes which may result in new molecular markers targets that can be used to 
diagnose and treat BRCA patient populations.  
1.3 Personalized drug response prediction in cancer 
The computational identification of novel driver genes and pathways and the integration of 
genomic data to discover alternative subtypes have set the stage to accurately portray the 
molecular and clinical profiles for a cancer patient. The next step in personalized medicine is to 
accurately predict a cancer therapy for individual patients in the context of the newfound 
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genomic and clinical diagnostic tools [13]. This is crucial to guide clinicians to assign the most 
effective therapeutic treatments individual cancer patients to ultimately combat the cancer and 
improve the quality of life [46][47]. One of the most promising personalized treatment strategies 
available to physicians is the prescription of drugs that target the driver genes of the patient [11]. 
For example, a lung cancer patient with an aberrant epidermal growth factor EGFR may respond 
well to a tyrosine kinase inhibitor which inhibits EGFR [48] while a breast cancer patient with an 
aberrant Her2/ERBB2 receptor may respond well to a monoclonal antibody, Trastuzumab, that 
targets the Her2/ERBB2 receptor [49]. The goal of computational methods that recommend drug 
treatment is to provide a framework which assigns the right targeted therapy to the right patient 
based off of the patient’s molecular signature information.     
 
Modeling the effect of cancer drugs is ripe with many major challenges. On the treatment side, 
cancer treatments work under a variety of drug mechanisms, each with unique indications, and 
contraindications which add many confounding variables to the precision and reliability of the 
prediction of the response of the targeted therapy [50]. Even in targeted therapies, cancer drugs 
have complex interactions with cell lines in which the interaction between the drugs and the 
targeted pathways are not well understood in many cases [51]. On the disease side, Cancers are 
multifactorial genetic diseases that are heterogeneous and operate under different disease 
mechanisms from patient to patient [52].  
 
The majority of data available for drug response analysis comes from cell lines compendiums 
such as The Genomics of Drug Sensitivity of Cancer (GDSC) [53] and the Cancer Cell Line 
Encyclopedia (CCLE) [54]. Cell line information has spawned many of the landmark studies in 
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drug response research. One example comes from the National Cancer Institute’s (NCI) 
DREAM7 project, where contestants predicted the drug response of “hidden” BRCA cell lines 
using RNA-seq data from training cell lines. Other cell line studies include Dong et al.’s machine 
learning model which uses Support Vector Machines (SVM) predicting the drug response of 
GDSC cell lines [55]; CancerDP, a drug prioritization method based on SVM with F-stepping 
feature selection [56]; A linear model study that calculated the drug response or Lymphoblastic 
cell lines using a linear model [57]. Most recently, a flagship study modeled drug response 
predictions through an ensemble method by identifying functionally impactful and unique 
Cancer Functional Events (CFEs) [58]. However, results from cell line studies is not without 
drawbacks. Experimental procedure differences between the major cell line compendiums have 
shown inconsistent drug response when the same drug is treated with the same cell line [59] 
Additionally, cancer tumors do not reside in a closed system. Tumors react closely with normal 
cells and the patient’s environment [60].  
 
Ideally, a drug treatment model built on real patient data and histories such as one utilizing 
TCGA data would accommodate these factors; however, such a model would need to be able to 
handle the added complexity and separate out the important features. Some methods have been 
developed to model drug effectiveness in drug response. The authors of [61] utilized a linear 
Ridge-Regression model to bridge the gap using in vitro gene expression models to make 
predictions in cancer patients. While gene expression models have shown a degree of success, 
gene expression models alone have been found to be insufficient in predicting drug response in 
some cancers [62]. The IntOGen platform has also built a drug recommendation model based on 
the proximity of the driving cancer gene to the drug target [63]. The identification of targetable 
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genes was expanded using the EMD model, which identified a list of candidate drivers using 
integrated gene expression, mutation, copy number and network information with potential drug 
targets for the drivers [64]. Another method GOPredict [63] integrates both genomic and 
pathway data to provide a ranked drug list of potential targets [65]. Most recently, Zhang et al. 
[66] developed a method ElasticNet Regression machine learning method that predicts the 
clinical response of a drug directly from TCGA molecular signature data using mRNA 
expression, mRNA expression, methylation, or copy number individually. However, this method 
has been hampered by several significant limitations. No model presented in their paper 
predicted drug response with a higher AUC of 0.7 when compared to the actual prediction. 
Additionally, the lack of a filter for curated cancer genes has led to overfitting due to the 
incorporation of low-information and redundant variables in the model. In this dissertation, we 
describe a novel method in drug response prediction and recommendation which addresses the 
limitations of previous methods by only using high-impact biological features to prevent 
overfitting as well as integration of multiple types of genomic features to increase the reliability 
of the model. 
 
1.4 Contribution of the dissertation 
 
While the aforementioned computational methods in driver detection have greatly contributed to 
our understanding of cancer progression from both an individual gene and a driver pathway 
perspective. The goals in driver detection addressed in the dissertation are two-fold: 1) the ability 
to precisely detect individual rare drivers that are potentially obscured by conventional methods 
and 2) the ability to describe in a biological context the interaction of multiple driver genes 
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working together. The work in this dissertation also seeks to explore potential clinical 
application. We use the insights highlighted by our driver detection methods as a guide to the 
identification of novel clinical subtypes using driver genes as important features for 
classification. Additionally, we use the integrated knowledge from drivers and other genomic 
sources to develop a new approach which prioritizes and predicts the response of cancer drugs.  
 
In Chapter 2, we introduce a method called DawnRank [67] that detects driver genes using data 
from a single patient sample. By only using data from an individual patient sample rather than a 
large cohort, we identify personalized, patient-specific drivers. The single patient approach 
detects drivers regardless of mutation frequency, thereby allowing us to focus on potential rare 
(infrequent) drivers. DawnRank ranks potential driver genes based on their impact on the overall 
differential expression of its downstream genes in the molecular interaction network. Mutated 
genes with a higher ranking are more likely to be drivers. DawnRank has been shown to 
outperform previous methods in detecting known, biologically-verified driver genes, while also 
proposing potential novel and rare driver genes. In Chapter 2, we explore the biological 
significance of the DawnRank driver genes, by using the DawnRank scores as the basis for a 
diagnostic tool to identify subtypes in breast cancer. In this analysis, we performed a consensus 
clustering on the DawnRank score on genes with mutation and copy number alterations to 
identify breast cancer subtypes. This method is novel in its application as it clusters BRCA over 
an integrated dataset of both mutation drivers and copy number drivers simultaneously. Our 
framework identified five alternative BRCA clusters which we compared to existing BRCA 
clinical subtypes as well as the established PAM50 gene expression subtype, and we identified 
potential driver genes that may serve as molecular markers for each of these subtypes.  
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With respect to driver pathways, while current methods such as Dendrix, Multi-Dendrix and 
CoMEt all have the ability to identify driver subnetworks/pathways involving multiple driver 
genes, the aforementioned methods are typically inefficient when applied to large-scale datasets 
with large values of their relevant parameters. Some of these methods are randomized in nature 
and no guarantees exist that multiple runs of the methods will produce compatible results. 
Almost all methods are only able to identify a small number of modules of limited size as cluster 
sizes are critical algorithmic parameters from the perspective of computational tractability. Most 
importantly, they have to be redesigned or restructured whenever new biological information is 
included in the discovery process. Chapter 3 introduces a novel method called Cancer 
Correlation Clustering C3 [68] which addresses the shortcomings of the existing methods. C3 
uses a new agnostic optimization framework specifically developed and rigorously analyzed for 
the driver discovery task that allows for the integration for flexible biological data from multiple 
sources such as coverage, mutual exclusivity, expression data and network pathway information. 
C3 has low computational cost compared to previous methods, and it allows for adding relevant 
problem constraints while retaining good theoretical performance guarantees. 
 
Chapter 4 of the dissertation introduces a novel method, Scattershot. Scattershot addresses 
several of the limitations of previous methods in order to develop a drug prioritization tool that 
assigns the right drug to the right patient. The data that Scattershot uses is from real patient, 
TCGA data, rather than the closed-system in vivo cell line studies. Scattershot models the drug 
recommendation problem as a multilabel machine learning problem [69] in which we develop 
ensemble classifiers from multiple genomic sources such as mutation, expression, copy number, 
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and pathway-level information as well as clinical variables. Scattershot uses the multilabel 
framework to build binary classifiers that predict the drug response of an individual drug while at 
the same time, aggregating multiple pairwise binary classifiers comparing pairs of drugs in a 
drug list to prioritize the drug rankings. We compared Scattershot’s treatment predictions in 
cancer patients to the treatments actually assigned to the patient by physicians and we found 
Scattershot’s predictions are mostly in line with the physician recommendation, outperforming 
the previous models. 
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Chapter 2: Integrated Mutation and Copy Number Driver Analysis Identifies Molecular 
Subtypes of Breast Cancer1 
 
2.1 Introduction 
 
Breast cancer remains the second leading cause of cancer related death in women each year [1]. 
Breast cancer is a heterogeneous disease with multiple subgroups. Patients in different subgroups 
have different prognoses, variable first sites of metastasis, and differential response to targeted 
therapeutics. Currently, the estrogen-independent breast cancers have the worst prognosis, fewest 
therapeutic options, and no currently approved targeted therapies. Standard of care includes 
chemotherapy and radiation therapy [38]. Identification of targetable drivers in breast cancer 
could provide novel therapeutic targets. 
 
The discovery of the driving events in cancer has been the subject of years of research in 
personalized medicine [2], [19], [21]–[24]. However, these methods, while providing a starting 
point in identifying common drivers, are often challenged by limitations in identifying rare, 
patient-specific drivers. Most of the methods listed above select drivers based on categorize 
mutations based on recurrence, i.e., the most commonly occurring mutations are more likely to 
be drivers [16], [17], and thus are disadvantaged due to the fact that they require a large number 
																																																						
1	The description of the DawnRank method in this chapter is based on a published paper in 
Genome Medicine and is referred to in the dissertation as “J. P. Hou and J. Ma, 
“DawnRank: discovering personalized driver genes in cancer,” Genome Med., vol. 6, no. 7, 
p. 56, 2014” 
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of patient samples to generate reliable results and lack the ability to discover rare and patient-
specific drivers. Other methods such as PARADIGM-Shift are designed to determine drivers in 
small pathways and often require detailed previous knowledge of specific pathways and focus 
genes to operate effectively. New methods are needed to identify novel and rare drivers when we 
do not have much prior knowledge of the tumor. 
 
It is now acknowledged that individual tumors of the same type are highly heterogeneous and 
have diverse genomic alterations [70], [71]. This stems from the “long-tail phenomenon” which 
states that cancer mutations are characterized by a small number of frequently mutated genes and 
a large number of infrequently mutated genes [72], [73]. Discovering rare drivers in the long tail 
of genetic alterations remains difficult. Therefore, we urgently need methods to assess the impact 
of patient-specific and rare mutations from individual tumor samples in order to elucidate 
personalized molecular drivers.  
 
Large efforts to identify the genetic underpinnings causing breast cancer have led to 
unprecedented amounts of both DNA and RNA genomic data. However, the significance of 
these alterations often is not well understood.  Copy number alterations (CNA), are known to be 
an early, common, and critical factor in the development of breast cancer. It is much more 
common across the TCGA cohort and has been shown to be an early event in the development 
from normal breast to pre-invasive cancer to invasive and metastatic tumors. CNAs, in 
conjunction with mutation-based alterations have been used to define and distinguish cancer 
subtypes in the past. Mutation and Copy Number alteration markers have used as factors to 
identify specific subgroups within Luminal breast cancers [45]. These driver genes present a 
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unique perspective in stratifying breast cancer subgroups [74]. Patient subgroups can be treated 
using targeted therapy directly aimed at the driver genes that that define the subgroup [75]. The 
implications of this are especially important in treating Triple Negative Breast Cancers (TNBC) 
which are defined by their lack of targeted therapeutic targets and poor overall prognosis [76]. 
Therefore, an integrated approach that identifies patient subgroups based on their driver genes 
may provide alternative targets in breast cancer targeted therapy. 
 
The identification of driver-defined subtypes requires a reliable method to identify the driver 
genes in a given cancer patient. One method that identifies personalized driver alterations in 
cancer is DawnRank [67]. DawnRank detects driver genes using data from a single patient 
sample. By only using data from an individual patient sample rather than a large cohort, we 
identify drivers in a personalized fashion. DawnRank allows for the integration of mRNA gene 
expression, DNA mutations, and DNA copy number data. The proportion of drivers from CNA 
as compared to mutation is not well known. Additionally, it is largely unknown if drivers on an 
individual tumor level are consistent within and across subtypes or private to a tumor. By 
applying DawnRank to TCGA breast cancer data, an understanding of the biology driving breast 
cancer can be explored with the hopes of identifying alternative, tractable therapeutic targets 
especially in estrogen-negative breast cancer. 
 
2.2 Results 
 
We applied DawnRank to the TCGA datasets. For evaluation purposes, we applied DawnRank to 
512 glioblastoma multiforme (GBM) samples, 504 breast cancer (BRCA) samples, and 572 
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ovarian cancer (OV) samples in TCGA. The datasets we used in this work include gene 
expression and coding-region mutation data for three cancer types generated by TCGA [44], 
[77], [78]. The data was accessed on May 20, 2013. The mutation data we used included non-
synonymous point mutations and insertions and deletions (indels) in coding regions. We first 
showed that DawnRank outperforms two pathway-based methods DriverNet and PARADIGM-
Shift. We then used the results of DawnRank to determine both potential novel drivers (new 
genes mutated frequently), and more importantly, potential rare and personalized drivers that 
previously could not be assessed by other methods. The discussion of potential novel and rare 
driver alterations as well as an in-depth comparison of DawnRank to other methods can be found 
in the DawnRank paper [67]. 
 
We then applied DawnRank to discover BRCA subtypes. We developed a framework for an 
integrative analysis of somatic mutations and copy number alterations that identified five breast 
cancer molecular subtypes within a TCGA breast cancer cohort of 351 patients weighted to be 
representative of a BRCA population using known subtypes. An overview of our method is 
shown in Figure 2. For this study, we utilized the Cancer Genome Atlas [44] as the discovery 
dataset and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 
[43] as a validation set. DawnRank was used to identify candidate driver genes. 
ConsensusClusterPlus [79] was then applied to discover subtypes of breast cancer based on 
driver alterations with a classification to nearest centroids classifier (ClaNC) [80]. Consensus 
Cluster Plus identifies stable clusters by assigning a patient into a cluster through a thousand runs 
of randomized patient sample, while ClaNC provides a feature compact method that predicts the 
class of a sample using the fewest features possible. Association with PAM50 [36] subtype and 
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clinical characteristics were assessed. Finally, we defined subtype-specific candidate drivers with 
both an Analysis of Variance (ANOVA) and significance analysis of microarray (SAM) [81]. 
The resulting alteration-based clusters yielded five potential BRCA subgroups with strong 
associations to the PAM50 gene expression clusters and the ER/PR/Her2 clinical classifications. 
We identified multiple sub-chromosomal altered hotspot regions encompassing candidate and 
subtype-specific, potentially new breast cancer drivers.  
 
2.2.1 Comparison of DawnRank to previous methods 
 
We evaluated the performance of DawnRank’s ability to identify known drivers and compared it 
with DriverNet and PARADIGM-Shift. As mentioned above, we utilized CGC as an 
approximate benchmark of known drivers. Here, we implicitly assume that all non-synonymous 
mutations in driver genes are potential driver mutations if they are selected by a method. We 
performed two separate comparisons. (1) We compared DawnRank to DriverNet over a large 
network in order to evaluate the performance of the two methods using a large human interaction 
network (which PARADIGM-Shift is not able to work with practically). (2) We also compared 
DawnRank to PARADIGM-Shift and DriverNet over a smaller, but well-annotated gene network 
based on KEGG in order to determine the effectiveness of the three algorithms in smaller 
networks. The network used in the first comparison was the same network described earlier. The 
network used in the second comparison was a smaller network built from the aggregation of the 
KEGG cancer pathways with 1,492 gene nodes and 8,070 edges. We ran DriverNet version 
1.0.0, defining a differentially expressed gene using their default settings of 2 standard deviations 
(http://www.bioconductor.org/packages/release/bioc/html/DriverNet.html), and we ran 
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PARADIGM-Shift version 0.1.9 using the suggested global-rank transformation for expression 
data (http://sysbio.soe.ucsc.edu/paradigm/tutorial/). To facilitate the comparison, we applied the 
Condorcet rank aggregation (see Methods) for the DawnRank scores based on individual patient 
samples to provide the consensus population-level driver scores. For each comparison, we used 
the following three measures (Precision, Recall, and F1-Score). 
 
Precision, recall and F1 scores were based on the top N genes. We first evaluated the 
performance between DawnRank and DriverNet. In general, DawnRank outperforms DriverNet 
in all three cancer datasets with respect to CGC (Figure 3). Although DriverNet performs 
comparably in ranking the top genes in GBM, it has poorer performance in OV and BRCA. A 
potential explanation of the difference may lie in the total number of mutations in the three 
cancer datasets. GBM had 5,478 mutations over 599 genes, while OV had 13,520 mutations over 
4,968 genes and BRCA had 11,900 mutations over 5,205 genes. The numbers indicate that there 
may be more passenger mutations in BRCA and OV and DawnRank is less affected by noise 
than DriverNet. An illustration of this is DriverNet’s ranking of the gene TTN as a top 5 driver in 
both BRCA and OV. TTN is the longest gene in the human genome and recent TCGA analysis 
has suggested that that higher mutation rate in TTN is likely to be artifacts [78]. TTN was not 
ranked among the top 60 genes in any cancer according to DawnRank. We then evaluated the 
performance of DawnRank, PARADIGM-Shift, and DriverNet using the smaller KEGG 
network. Overall, DawnRank outperforms both DriverNet and PARADIGM-Shift in terms of 
precision, recall, and F1 scores using CGC as a standard (Figure 4) or the Pan-Cancer results as a 
standard. In BRCA, although some known drivers such as TP53 and ATM were detected by 
multiple methods, DawnRank detected important known driver genes in the top 10 such as 
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CDH1, PIK3R1, and BRCA1 in breast cancer which were not detected by either PARADIGM-
Shift or DriverNet as top ranking drivers. 
 
2.2.2 Identification of driver-based subtypes 
 
In order to define the genetic drivers of breast cancer through an integrated analysis of gene 
expression, copy number, and mutation, we applied DawnRank to BRCA using a custom 
balanced cohort in TCGA, which samples a cohort where the proportion of each PAM50 subtype 
matches that of the population. Genes with cohort-wide DawnRank p-values ≤ 0.05	were 
considered for clustering to define driver-subtypes. 65 copy number altered genes and 38 
mutated genes were significant across the cohort (Figure 5A). These genes are selected by 
DawnRank to maximize pathway impact and driving potential. The copy number altered genes 
cluster along 1q gains, 8q gains, 11p loss, and 16p loss (Figure 5C-F). Running 
ConsensusClusterPlus on TCGA tumors with 1000 iterations of ConsensusClusterPlus with 80% 
resampling of genes and samples, we identified five as the ideal number of clusters by observing 
the maximum cophenetic correlation when testing k = 2 to k = 10. We compared the clusters 
after 25 different runs of ConsensusClusterPlus and observed consistent clustering results with a 
pairwise Rand Index of 0.97. Centroids for each subtype were built with ClaNC classifier with 
the feature parameter of 11, causing the least amount of misclassification in TCGA.  
 
2.2.3 Driver-subtypes reflect the genomic heterogeneity of breast cancer 
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To classify the driver-subtypes in the context of previously defined clinical predictors and 
molecular taxonomy, we examined the correlation with PAM50 subtype and known clinical 
predictors. Plotting Pearson residual for each driver-subgroup, we observe subgroups highly 
correlated to the PAM50 molecular subtypes (Figure 5B). The first cluster (red) is weakly 
positively correlated to both Luminal A and B PAM50 subtypes. The second subgroup 
demonstrates strong association with Basal-like and weakly positive correlation with Her2. The 
third cluster demonstrates an association with Luminal B subtype and a weak association with 
Her2-enriched PAM50 subtype. The fourth alteration cluster is consistent with previous work 
demonstrating shared genomic features between Luminal B and HER2-enriched PAM50 
subtypes [82]. The two remaining alteration clusters, “Luminal A1” and “Luminal A2”, are both 
strongly associated with the Luminal A PAM50 subtype.  
 
Since the mutation data is used for clustering, it is unsurprising that multiple mutation markers 
have strong associations with the alteration clusters which we confirmed using the Chi-square 
test for association. We tested mutation status of TP53, PIK3CA, GATA3, MAP2K4, and 
MAP3K1 due to their previously defined significance as drives by MutSig [44]. TP53 mutations 
are highly correlated with the Basal/Her2 and Luminal B/Her2 alteration clusters (p-value < 2e-
16). PIK3CA and GATA3 mutations are highly associated with the Luminal B and Luminal A2 
alteration clusters (p-value < 2e-16 and p-value = 0.043) [83]. These results confirm previously 
identified mutational and PAM50 subtype associations [44].  
 
2.2.4 Driver-subtypes correlate with Estrogen Receptor status, Progesterone status, and tumor 
stage 
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We next examined the correlation of each driver-subgroup to known clinically predicted values 
including: estrogen receptor (ER) status, progesterone receptor (PR) status, and Her2 receptor 
(Her2) status, tumor stage (T), node status (N), metastasis status (M). Clusters demonstrated 
significant association with 3 of the 6 tested clinical and mutation features, including ER, PR, 
and T. Interestingly, Her2 did not significantly associated with any subgroup. As expected, the 
three Luminal alteration clusters (Luminal A1, Luminal A2, and Luminal) demonstrated positive 
signals with ER and PR (Chi-squared test for association p-value < 2e-16). Tumor Stage 
associated with Luminal A2 group p-value = 0.001. These results further validate our 
classification scheme to recapitulate known clinical markers and biological subtypes. 
 
2.2.5 Subtype-defining drivers 
 
To define subtype-specific drivers, each driver (68 CNAs and 38 mutations) are tested by 
ANOVA for overall variation among the subgroups, and one class against all others to define the 
driver-subgroup specific to the driver with the significance analysis for microarray (SAM). For 
large, focal, CNAs we limited candidate drivers to the top two gene markers to represent the 
focal length alteration. ANOVA identified 11 copy number altered genes and 8 somatically 
mutated genes significantly associated with one subtype (Figure 6A). SAM analysis identified 37 
significantly altered genes within the driver-subtypes under a false discovery rate of 0.05 (Figure 
6B). Comparing results across both statistical analyses, we found five significant driver genes 
(ARF1, AKT3, PIK3CA, ATM and BCAR1) across both the ANOVA and SAM analyses.  
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For the Luminal driver-subtypes, we identified consistent drivers gained on chr1q across all three 
subgroups; however, subtype-specific candidate drivers are also present. BIRC3 (chr11) copy 
number loss is specific to the Luminal alteration cluster. 77.6% of the Luminal subtype has a 
copy number loss at BIRC3, and 66.0% of all BIRC3 alterations occur in the Luminal subtype. 
We visualized the network impact of BIRC3 within the Luminal driver-subtype (Figure 6C) 
compared to the network in the other driver-subgroups (Figure 6D). We identified a large 
downstream down-regulation of several genes within the network specific to the Luminal driver-
subtype (Figure 4C). In particular, PAK1 is the most distinct downstream differentially 
expression gene within the BIRC network for the Luminal subgroup but not in the other 
subgroups. PAK1 is two degrees of separation from BIRC3 and is a known oncogene that 
activates MAPK and MET signaling in cancer [84]. Our results suggest that PAK1 is highly 
overexpressed in Luminal subtype, which may be due to the deletion of upstream BIRC3. 
 
2.2.6 Subtype-specific driver CNAs in four chromosomal hotspots  
 
Specific regions of the genome are known to be commonly gained and lost within breast cancer. 
The drivers at these locations, however, are not well understood. Whether subtype-specific 
differences within each region of the genome selects for different driver genes is not known. We 
explored four known regions with a high prevalence of copy number alterations in BRCA to 
define subtype-specific drivers within each region including: 1q amplification, 8q amplification, 
11q deletion, and 16q deletion (see Figure 5C-F).  
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The chr1q amplification is one of most frequently occurring CNAs in breast cancer [85] [86]. 
Using a Chi-squared test, chr1q amplification is significant in the Luminal, Luminal A1, and 
Basal/Her2 clusters (p-value < 2e-16). In each of these clusters, chr1q copy number gains 
occurred in more than half of the samples with 76.2% alteration rate in samples in these three 
clusters as compared to only 12.2% alteration rate in the other two clusters. The DawnRank 
drivers in chr1q significant in these three driver-subgroups include AKT3 (25/335, 7.1%) and 
NCSTN (23/335, 7.1%). AKT3 is an integral member of PIK3CA signaling pathway, responsible 
for many vital cell functions such as growth and apoptosis [87]. NCSTN, a recently identified 
candidate target for altered Notch signaling activity within Basal-like breast cancers, provides 
the structural support for Notch signaling and is required for GSC cleavage of Notch receptor 
[88] 
 
Chr8q is a frequently occurring copy number gain with subtype defining features [89]. Chr8q 
amplification is significant in the Luminal B/Her2 (95.9% alteration rate) and Basal/Her2 (67.0% 
alteration rate) but not in the Luminal A related subtypes (20.2% alteration rate; Chi square p < 
2e-16). LumB/Her2 is significant for MYC (driver in 4.6% samples, SAM p-value=5.7e-8) and 
NCOA3 (driver in 2.8% samples, SAM p-value=1.47e-7). MYC is a key regulator of cell growth, 
proliferation, metabolism, differentiation, and apoptosis [90]. NCOA3 is a nuclear receptor that is 
known to be overexpressed in breast cancer and involved in estrogen-mediated cancer cell 
proliferation [91].  
 
Chr11q loss is primarily defined by the Luminal alteration cluster. Subtype defining driver genes 
in chr11q include BIRC2 and BIRC3 (drivers in 5.4% samples). These genes function by 
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inhibiting apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and 
TRAF2 [92]. 
 
The fourth major hotspot is chr16q loss. Previously associated with Luminal A breast cancer 
[93], chr16q loss is consistently associated with our three Luminal driver-subgroups.  This region 
is marked by CDH1 (driver in 16.5% samples) and TRADD (driver in 4.0% samples). CDH1 has 
prominent role in epithelial differentiation and may play a role in tumor differentiation and 
metastasis [94] . TRADD codes for an adaptor molecule that interacts with TNFRSF1A/TNFR1 
and mediates programmed cell death signaling and NF-kappaB activation [95]. TRADD also 
interacts with key drivers TRAF and CASP3 genes.  
 
2.2.7 Validation using METABRIC dataset  
 
Utilizing gene expression, recently published mutation data, and copy number data from the 
METABRIC dataset (n = 339 patients), we calculated the DawnRank scores for each tumor. We 
then applied ClaNC classifier on the 103 driver genes identified in the TCGA cohort to classify 
METABRIC samples into the 5 subtypes. We associated the 5 METABRIC driver-subtypes with 
PAM50 subtypes (Figure 7A). Similar to the TCGA alteration clusters, four of the METABRIC 
subgroups significantly associate with PAM50 subtypes (Chi-squared test for p-value=1.2561e-
10). The fifth subtype is associated with both Her2 and Luminal B. A Chi-squared based 
Goodness-of-Fit test confirmed that the distribution of between the TCGA and METABRIC 
results share the same distribution as compared to the PAM50 results (p-value=0.2128). These 
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results from the ClaNC classification of METABRIC driver-subgroups validate the TCGA 
driver-subgroups. 
 
Using the METABRIC dataset, we compared the overall survival time from the alterations 
clusters from METABRIC subtypes (Figure 7B) to that of PAM50 (Figure 7C). Both the 
alteration clusters and the PAM50 subtype demonstrate significant differences in survival within 
each group (p-value = 0.0251 and p-value = 0.0186), with the Basal-associated subgroups 
showing worsened overall survival.  
 
2.3 Discussion 
 
It is now acknowledged that individual tumors of the same type are highly heterogeneous and 
have diverse genomic alterations. Therefore, we urgently need novel methods to identify patient-
specific and rare drivers from individual tumor samples in order to elucidate personalized 
molecular mechanisms in different types of cancer. The goal of DawnRank is to integrate 
mutation data, gene expression, and network information to discover drivers in a personalized 
manner. We applied DawnRank to a large number of TCGA samples. By comparing to previous 
studies, our results demonstrated the effectiveness of DawnRank: (1) Despite its single-patient 
scope, DawnRank detects common and known drivers with as much or more precision than 
existing methods. (2) DawnRank can identify rare and novel genes that are potential drivers to 
specific patients. We believe this method will complement existing driver identification methods 
and will help us discover potential personalized drivers. The application to breast cancer 
	 27	
subtypes further demonstrates that the rare drivers predicted by DawnRank provides new insights 
into the molecular explanations of cancer subtypes with higher tumor heterogeneity. 
 
Using DawnRank, we present a new and different classification of breast cancer and subtype-
specific driver analysis of both copy number and mutation data. Utilizing both TCGA as a test 
set and METABRIC as the validation set, we demonstrate five robust driver-subtypes. Three 
subtypes correlate highly with the Luminal A subtypes, one with Basal/Her2, and the final with 
LumB/Her2. Additionally, the subgroups correlate with known clinical markers such as the 
estrogen and progesterone receptors with the Luminal subtypes, TP53 mutation in the 
Basal/Her2 subtypes, and worsened overall survival in the Basal/Her2 subtype. 
 
Known hotspots of copy number alteration in breast cancer, including 1q amplification, 8q 
amplification, 11q loss, and 16q loss, demonstrate subtype-specific differences. Chromosome 11 
loss is specific to Luminal subtype including BIRC3 and CBL loss. BIRC3 network analysis 
demonstrates loss of BIRC3 and a strong up-regulation of PAK1, a known oncogene downstream 
of BIRC3. A second interesting result is the loss of CBL, an E3 ubiquitin protein ligase which 
recognizes known oncogenes including FGFR2, KIT, and PDGFRA. CBL loss has not been 
previously described in the context of Luminal breast cancer. Targeting of FGFR family 
members with dovitinb has been showing to be effective in a small cohort of breast cancer 
patients in Phase 2 trial [96]. CBL loss could be a second marker for FGFR sensitivity in patients 
who lack FGFR amplification but still may be dependent on this pathway.  
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Integrating gene expression to evaluate the impact of a genomic alteration allows for novel driver 
identification such as the loss of BIRC3 and CBL playing major roles in defining the Luminal A 
subtype. Novel therapeutic targets are desperately needed for breast cancer patients, especially 
triple negative (TNBC) patients who lack estrogen receptor (ER), progesterone receptor (PR) 
overexpression or amplification of the human epidermal growth factor (HER2). In the metastatic 
setting, TNBC patients often do not benefit from the addition of systemic therapy. The paucity of 
systemic, targeted anti-cancer therapies in these patients begs for new treatment options. 
Improving our understanding of the underpinning molecular drivers of this subgroup are 
necessary to develop better targeted and more effective therapies.  
 
Future in vitro and in vivo confirmation will be needed to confirm our findings. We are also 
limited by the biases in the curated pathway used to evaluate the networks. Finally, assessment 
of these drivers through both therapeutic selection (comparing pre-treatment and post-treatment 
samples) and the selection of these drivers through the metastatic process are needed. Metastases 
are the leading cause of cancer related deaths, and often a small percentage clone in the primary 
causes seeding of distant metastases. Thus, drivers identified in the primary may not be the main 
causes of metastasis or the genes that need to be targeted to halt metastatic progression. Future 
studies on large cohorts of matched primaries and metastases will soon answer these questions. 
 
The heterogeneity of breast cancer has long been described and understood from a clinical, 
histopathologic, and molecular lens. Through DawnRank, we were able to capture this 
heterogeneity and assess novel molecular drivers for each breast cancer subtype. Future 
functional studies confirming the role of these drivers in a subtype-specific manner are needed in 
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order to lead to novel therapeutic development. Incorporation of mutations, copy number 
alterations, and gene expression confirm the importance of evaluating not only mutations but 
also copy number variations in understanding the underlying biology driving breast cancer.  
 
2.4 Methods 
 
2.4.1 DawnRank algorithm 
 
 
Our method ranks genes according to their impact on the perturbation of downstream genes, i.e., 
a gene will be ranked higher if it causes many downstream genes, directly or indirectly in the 
interaction network, to be differentially expressed. DawnRank views the gene network as a 
directed graph. We adopted the random walk approach used in PageRank [97], [98] to model this 
process iteratively.  
 
In DawnRank, a gene will possess a higher impact score (i.e., rank) if the gene is highly 
connected to differentially expressed downstream genes (directly and indirectly connected). 
Driver genes tend to display a high-degree of connectivity within the gene network [99], [100]. 
For example, using the number of outgoing edges alone, known driver genes as classified by the 
Cancer Gene Census (CGC) [101] have a mean and median of 31.45 and 12 outgoing edges, 
respectively, whereas genes not typically classified as drivers (not in CGC) have a mean and 
median of 17.73 and 3 outgoing edges, respectively. The higher number of outgoing connectivity 
of known driver genes suggests that the PageRank model would be appropriate to prioritize 
driver genes based on their impact in the gene interaction network. PageRank has had several 
adaptations in genomics. GeneRank utilized PageRank to rank the importance of genes in a 
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molecular network [102]. PageRank derivatives (such as SPIA [103]) have also been used to 
analyze pathway-level importance. More recently, it was utilized to predict clinical outcome of 
cancer patients based on gene expression [104] and to assist subtype identification [105]. Such 
approaches also show similarity in nature to modeling network impact as a heat diffusion process 
as used in HotNet [106] and TieDIE [107]. DawnRank builds on the original PageRank 
algorithm by providing a way to model a network’s directionality with more stable rankings by 
utilizing dynamic damping factors (see below). 
 
DawnRank views the gene network as a directed graph. Let N be the number of nodes (in our 
case, genes) in the directed graph, and A be the adjacency matrix representation of the graph, a 0-
1 matrix (if node i links to j, then 𝐴'( = 1). Note that the current 0-1 adjacency matrix can be 
naturally extended to consider weighted edges to further distinguish different gene-gene 
interactions.  
 
We define the rank of each gene iteratively: 
𝑟(,-. = (1 − 𝑑()𝑓( + 𝑑( 𝐴('𝑟',𝑑𝑒𝑔'7'8. , 1 ≤ 𝑗 ≤ 𝑁	 (2.1)	𝑟,	is the rank in the 𝑡,= iteration. The output of the rank describes a gene’s overall impact on the 
network: the higher the rank, the higher the impact of the gene. 𝑑 is the damping factor, a 
parameter representing the extent to which the ranking depends on the structure of the graph. In 
DawnRank, the damping factor is individualized based on gene connectivity (discussed below). 𝑓 is the prior probability of the gene which we set to the absolute differential expression. The 
absolute differential expression is the absolute value of the difference of the log scale tumor and 
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normal expression values. The 𝑑𝑒𝑔' = 𝐴('7(8.  is the in-degree of i, or the number of incoming 
nodes to i. This differs from the original PageRank definition of 𝑑𝑒𝑔', which was the out-degree 
of i. A webpage’s PageRank is dependent on the rank of the webpages that link to it (incoming 
edges), whereas our gene’s rank is dependent on the rank of the genes that it links to (outgoing 
edges).  
 
The zero-one gap problem refers to the potential pitfall that assigns biased ranks to some nodes 
[108]. When trying to rank nodes with 0 incoming edges, known as “dangling nodes”, the 𝑑𝑒𝑔'	will be 0, arising to a divide-by-zero error. In our real gene network data, 15.5% of all 
genes do not have any incoming edges. The initial PageRank algorithm attempts to handle the 
problem by setting the damping factor to be 0 for such genes, while using the damping factor 
0.85 for all other nodes. If we use this approach, the ranks of genes with no incoming edges will 
be based solely on its differential expression (and not the network structure). However, this 
correction in itself causes a large gap in the damping factor for genes with 0 and 1 incoming edge 
This large gap in the damping factor can cause a drastic change in the ranking of the gene when 
an incoming edge is added to the gene which in turn may cause unstable rankings [108]. An 
unstable ranking system is especially concerning to gene network data, as it is still not a 
complete representation of all interactions among genes [109]. Therefore, small modifications 
and additions to certain gene interactions may significantly alter the rankings of potential drivers. 
To address this problem, we utilize dynamic damping factors [108], where each gene possesses 
an individualized damping factor based on the number of incoming edges to that gene (Eq. 2). As 
the number of incoming edges increases, the damping factor gradually rises to incorporate more 
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connectivity information into the ranking of the gene, therefore no large gap is observed from 0 
in-degree and 1 in-degree. 
𝑑' = 	 𝑑𝑒𝑔'𝑑𝑒𝑔' + 𝜇	 (2.2)	
The parameter 𝜇 follows a Dirichlet prior trained from maximizing the values of 𝜇 over 100 
random samples. We selected the 𝜇 value of 3 because it had the highest average DawnRank 
scores for known drivers in CGC. Overall, the dynamic damping factor mitigates the large 
change in the damping factor in nodes with 0 and 1 incoming edges by gradually increasing the 
damping factor as the gene’s in-degree increases, thereby creating more reliable and more stable 
rankings. We also show that DawnRank performs more reliably with a dynamic damping factor 
than a static damping factor on the TCGA datasets. 
 
In addition to the iterative version of DawnRank, the method can also be presented in matrix 
form: 𝑟,-. = (1 − 𝑑)𝑓 + 𝑑𝑀×𝑟,	 (2.3)	
where 𝑟,,	𝑑, and 𝑓 are N×1 matrices to represent the rank, gene-specific damping factor, and the 
gene expression, respectively, and 𝑀 is the transition matrix defined by: 
𝑴 =	 𝐴.,.𝑑𝑒𝑔. ⋯ 𝐴.,C𝑑𝑒𝑔C⋮ ⋱ ⋮𝐴C,.𝑑𝑒𝑔. ⋯ 𝐴C,C𝑑𝑒𝑔C 	 (2.4)	
 
DawnRank converges when there is no longer a significant update in the ranks. This is when the 
magnitude of the difference of the ranks between time 𝑡 + 1 and the previous time point 𝑡 falls 
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below a small 𝜀, which we set to 0.001, the same value suggested by [108]. DawnRank also 
stops when no solution is present after a maximum number of iterations, which we set at 100. In 
practice, DawnRank always converges for any reasonable µ between 0.01 and 20 within 20 
iterations. Nonetheless, there are corner cases at low damping factors (µ < 10I.J) where 
DawnRank either does not converge or converges very slowly. 
 
2.4.2 Rank aggregation for population rankings of drivers 
 
To aggregate the rankings of genes from individual patient samples to determine the most 
impactful drivers in a population (e.g., known drivers for the same type of cancer or a specific 
sub-type), DawnRank applies a modified version of the Condorcet method [110]. The Condorcet 
method is a voting scheme in which “voters” vote for the best “candidate” by submitting a rank-
ordered list of candidate preferences. The list of preferences is allowed to be either partial or full. 
The Condorcet method then selects a winning candidate by comparing every possible pair of 
candidates A and B and determining a “winner” by comparing the number of voters that 
preferred A to B and vice-versa. We applied the Condorcet method to the personalized rankings 
of genes to determine aggregate ranking of genes in a patient population. 
 
Although the Condorcet method is built to handle partial voting lists, one difficulty of 
implementing the Condorcet method is the lack of patient samples that possess the commonly 
mutated genes. Many pairwise comparisons are missing for many gene combinations due to the 
lack of patients that have mutations in both genes simultaneously. However, since DawnRank 
can output a ranking as an impact score for all genes regardless if a gene is mutated, we 
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evaluated pairwise comparisons of two genes based on patients with a mutation in at least one of 
the two genes. This approach avoids the use of non-mutated gene comparisons to calculate the 
aggregate score of genes, as the objective of DawnRank is to determine the altered genes that are 
the most impactful. However, since mutation recurrence is an important factor in detecting 
common drivers, we also implemented a penalty heuristic,	𝛿, a number between 0 and 1 in our 
approach to lower the ranking of a gene in a pairwise comparison that is not mutated. This 
penalty allows us to rank aggregate frequent drivers based on both impact and frequency. 
 PairwiseWinner 𝐴, 𝐵 = 𝐴		if	𝛿(𝐴)×𝑅𝑎𝑛𝑘(𝐴) > 𝛿(𝐵)×𝑅𝑎𝑛𝑘(𝐵)	𝐵																													otherwise 	 (2.5)	
where  𝛿(𝐴) = 𝛿												if	𝐴	is	NOT	mutated1																					if	𝐴	is	mutated 	 (2.6)	
 
We used the output from DawnRank, which we converted to percentile rank format, to represent 
the ranking of the gene. The penalty heuristic lowers the value of a non-mutated gene when 
comparing it against a mutated gene. This heuristic serves as both a means to prevent a rare 
mutation that is impactful in one patient from winning all pairwise comparisons (akin to a 
candidate winning just because one and only voter that voted for it ranked it higher than any 
other candidate) and to prevent a low impact, high frequency mutation from winning a pairwise 
comparison against high-impact genes that are not frequently mutated (akin to an unpopular 
candidate winning just because many voters had a low-preference vote for that candidate). We 
selected 𝛿 by running DawnRank over 100 random patient samples for various instances of 𝛿 
between 0 and 1 and calculating the precision with respect to CGC genes. We found 𝛿 to be 0.85. 
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2.4.3 Patient sample selection for BRCA subtype analysis 
 
We selected gene expression and copy number data from 871 TCGA samples and 1,992 
METABRIC samples. The gene expression is converted into a Z-score, and segmented CNAs are 
converted into a discrete copy number gene matrix. Significant copy number altered segments 
with segment means greater than 0 are assigned 1 while significant segments with segment 
means less than 0 are assigned -1, while all other regions are assigned 0. Using the hg19 gene 
annotation, genes that are completely encompassed within a segment (based on genomic 
location) are such that the segment’s discrete copy number value and all other genes are assigned 
0. DawnRank mutation scores are further distinguished with mutations in oncogenes represented 
as positive values and tumor suppressors as negative values. A gene mutation matrix is created 
by assigning -1 to mutations in known tumor suppressors and 1 to mutations in known 
oncogenes (based on publically available OncodriveRole data) and the value 0 is assigned to all 
others [111]. Overall survival data is calculated up to 10 years and plotted using a Kaplan-Meier 
survival curve. Patient samples with greater than 10-year survival are censored at the 10-year 
mark. An ANOVA analysis is performed to test for significant difference in survival within a 
patient group. We selected 500 samples from each TCGA and METABRIC. To keep the relative 
distribution of PAM50 subtypes consistent between the two datasets, we randomly selected 
TCGA samples based on the average distribution of PAM50 subtypes within the METABRIC 
cohort. The composition of samples based on the PAM50 molecular subtypes: 19.3% Basal, 
10.9% Her2, 39.5% Luminal A, and 30.3% Luminal B (Normal-like breast cancer not included). 
 
2.4.4 Alteration based subtype classification using consensus clustering 
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During clustering, ConsensusClustersPlus was used to partition the samples and features (driver 
genes), and builds an unsupervised hierarchical cluster from that particular data subset. Through 
iterations, a final agglomerative hierarchical consensus clustering using distance of 1-consensus 
values is completed and pruned to k groups. ConsensusClusterPlus is run on k = 2 to k =10 
groups with sample distances calculated using the Pearson distance over 1,000 iterations. To 
ensure that ConsensusClusterPlus rarely samples a subset where a patient has no driver 
alterations (which makes the Pearson distance calculation yield undefined numbers), we trimmed 
the TCGA and METABRIC datasets to only include samples with at least 5 driver alterations 
(TCGA n=351 and METABRIC n=339). Since ConsensusClusterPlus is not deterministic, we 
used 1,000 iterations to minimize the misclassification rate between different runs of 
ConsensusClusterPlus to less than 10%. Each iteration sampled 80% of samples of the total 
dataset and the corresponding pairwise misclassification rate of only two single iterations of the 
sample was 22%. We also sampled 80% of all features (all common drivers in TCGA and 
METABRIC) compared to only TCGA drivers (53/65=81%).  
 
2.4.5 Validation of the classifier 
 
ClaNC is a custom implementation of Linear Discriminant Analysis (LDA) that selects for 
features using regular t-statistics to account for class difference given a number of features and 
classes. Using a 5-fold cross-validation approach on misclassification, ClaNC calculates both the 
number of classes and the number of transformed features. We used ClaNC in the METABRIC 
validation section, and we used TCGA DawnRank alteration clusters through 
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ConsensusClusterPlus results as training with METABRIC data as testing. We found that ClaNC 
works optimally at reducing misclassification when k=5 at 11 transformed features with the 
misclassification rate of 0.223. In addition to the optimal parameter setup of the supervised 
ClaNC classifier, we also determined that 5 alteration subtypes were optimal in reducing 
misclassification, and thus 5 classes were selected.  
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FIGURES 
 
Figure 1: Overview of the DawnRank Method 
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Figure 2: A schematic diagram detailing the overall workflow in this work.  
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FIGURES 
 
Figure 3: A comparison of the precision, recall, and F1-scores for the top ranking genes in 
DawnRank and DriverNet. The X-axis represents the number of top ranking genes involved in 
the precision, recall, and F1 score calculation. The Y-axis represents the score of the given 
metric. 
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Figure 4: A comparison of the precision, recall, and F1 scores for the top ranking genes in 
DawnRank, DriverNet, and PARADIGM-Shift on a small network (defined from the KEGG 
database). The X-axis represents the number of top ranking genes involved in the precision, 
recall, and F1 score calculation. The Y-axis represents the score of the given metric. 
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Figure 5: Clustering result based on driver genomic alterations using TCGA data. (A) A 
landscape plot detailing the subtypes defined by driver genomic alterations in TCGA breast 
cancer samples. The columns represent the samples and the rows represent the DawnRank-
selected genes used in the clustering. The green entries represent copy num© gain (for CNA) and 
oncogene mutations (for point mutations). The red entries represent copy ©ber loss (for CNA) 
and tumor suppressor mutations (for point mutations). The intensity of the color reflects the 
DawnRank score. The tracks above the heatmap shows clustering results as well as comparison 
to other information such as PAM50 subtype, tumor stage, and ER/PR/Her2 status. (B) 
Correlation result between the ConsensusClusterPlus (CCP) and PAM50 subtypes. Positive 
associations are in blue and negative correlations are in red. The p-value at the bottom of the 
legend shows the p-value of the Chi-squared association test that determines the difference 
between the clusters. (C)-(F) The zoom-in view of the clusters with focal CNAs on 
chromosomes 1, 8, 11, and 16, as well as the key genes involved. 
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Figure 6: Subtype defining genes. (A) Genes selected from ANOVA analysis. (B) Gene selected 
from SAM analysis. (C) A network view in Luminal subtype detailing the gene interactions 
between BIRC3 and nearby genes in the network up to two levels downstream. Red nodes 
represent downregulation and green nodes represent overexpression. The intensity of the node 
represents the magnitude of gene expression. Edge thickness and color represent the distance 
between the gene in question and BIRC3. Magenta edges represent 1 degree of separation from 
BIRC3, black represents 2, and gray represents 3. (D) A network view of BIRC3 in non-Luminal 
subtypes. 
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Figure 7: Comparison with the results in METABRIC dataset (based on classifier trained from 
TCGA clusters). (A) Comparison between the METABRIC predicted subtypes and PAM50 
subtypes. (B) The K-M plot of the METABRIC predicted subtypes. (C) The K-M plot of the 
PAM50 subtypes. 
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CHAPTER 3: A new correlation clustering method for cancer mutation analysis2 
 
 
3.1 Introduction 
 
Rapid advances in high-throughput sequencing technologies have provided unique opportunities 
for analyzing large numbers of cancer genomes. However, the complexity of genomic alterations 
in cancer causes significant analytical and computational challenges that have to be overcome in 
order to fully characterize the functional roles of various mutations. In particular, as cancer 
genomes tend to contain a large number of diverse mutations (e.g., point mutations or copy 
number changes) most of which are neutral, one problem of significant importance is to identify 
a small set of mutations that perturb key biological pathways and have significant impact on 
tumorigenesis [10]. Hence, a central question in cancer genomics is how to distinguish “driver'' 
mutations, which contribute to tumorigenesis, from functionally neutral “passenger'' mutations.  
 
Many computational methods have been developed to facilitate the discovery of driver genes 
[19], [112]–[115], most of which rely on mutation counts. Due to the high level of inter-tumor 
heterogeneity, two patients with the same cancer may have vastly different drivers and as a result 
many cancer mutations occur with low frequency in the patient population. Therefore, 
approaches relying on simple estimates of recurrence or frequency of mutations usually do not 
work well in practice. To mitigate this problem, several recent approaches have integrated 
frequency analysis with pathway-based and network-based models in order to ensure high 
																																																						
2	This chapter appeared in its entirety in Bioinformatics and is referred to in the dissertation as  
“J. P. Hou, A. Emad, G. J. Puleo, J. Ma, and O. Milenkovic, ‘A new correlation clustering 
method for cancer mutation analysis.,’ Bioinformatics, p. btw546, Aug. 2016.” 
	 46	
accuracy of common driver mutation discovery [23], [67], [71], [107], [116]. Such methods have 
an advantage in so far that in addition to mutation analysis, they take into account gene 
interactions as an added source of prior knowledge. 
 
In parallel, methods have been proposed to identify driver pathways, i.e., groups of genes that 
may interact together in combinatorial patterns to promote tumorigenesis. [29] described a 
method called MEMo, and subsequently used it to show that mutually exclusive modules based 
on known networks can aid in determining groups of genes that contribute to tumorigenesis. 
These gene groups, or modules, are jointly highly recurrent, have similar pathway impact in 
terms of biological processes, and their corresponding mutations tend to be mutually exclusive, 
meaning that very often only one gene in each gene group is mutated at a given time in any given 
patient. This mutual exclusivity rule in cancer pathways is supported by the observations that, in 
general, one mutated gene suffices to perturb the function of its corresponding pathway. Multiple 
mutations would require significantly higher energy investments on the part of cancer cells, and 
are hence selected against. [30]  expanded the ideas behind the concept of MEMo with iMCMC, 
and provided a framework to integrate mutation data, copy number, and expression information 
into cancer network weights which they used to identify modules; they also performed multiple 
types of integrative cancer perturbation data analysis. Dendrix [31] was developed to identify 
driver pathways de novo using mutual exclusivity and coverage (patient coverage) principles, 
without relying on known network information that has the potential to improve the discovery 
process of new modules. MDPFinder [32] expanded on the overall framework of Dendrix by 
incorporating gene expression information to ensure that genes in discovered mutually exclusive 
pathways were also co-expressed. Multi-Dendrix [33] and CoMDP [34] improved on the 
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limitations of Dendrix and MDPFinder, respectively, by allowing their algorithms to find 
multiple co-occurring modules. More recently, CoMEt [35] was proposed to address an inherent 
bias in Dendrix and Multi-Dendrix that resulted in high frequency mutations being significantly 
more likely to be included in mutually exclusive modules.  
 
However, while methods such as Dendrix, Multi-Dendrix and CoMEt all have the ability to 
identify mutually exclusive modules de novo, they still have significant limitations.  
The aforementioned methods are typically inefficient when applied to large-scale datasets with 
large values of their relevant parameters. Also, some of these methods are randomized in nature 
and no guarantees exist that multiple runs of the methods will produce compatible results. 
Furthermore, almost all methods are able to identify only a small number of modules of limited 
size as cluster sizes are critical algorithmic parameters from the perspective of computational 
tractability. Most importantly, they have to be redesigned or restructured whenever new 
biological information is included in the discovery process. 
 
To overcome these and other shortcomings of existing methods, we introduce a novel method 
called Cancer Correlation Clustering C3 to directly tackle the problems of integrating diverse 
sources of evidence regarding driver pattern behavior and eliminating computational bottlenecks 
associated with large cluster sizes or cluster numbers. The C3 method uses a new agnostic 
optimization framework specifically developed and rigorously analyzed for the driver discovery 
task, in which patient data is converted into a simple set of weights used in the objective function 
that do not require the algorithm to change upon incorporation of new data sources. In addition 
to this flexibility, C3 has low computational cost, and it allows for adding relevant problem 
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constraints while retaining good theoretical performance guarantees. Furthermore, the algorithm 
outperforms CoMEt in three out of four evaluation criteria, where the three criteria depend on 
which weights are “emphasized” in the optimization problem: tuning the weights allows one to 
select which features to improve or emphasize. What the relevant constraints features are may be 
chosen by the user, although our analysis included coverage, mutual exclusivity, expression data 
and network pathway information. We also point out that the weights may be chosen so as to 
cater to the need of many other computational biology problems that involve optimization on 
graphs.  
 
To test C3, we ran extensive simulations for several cancer types (including breast cancer, kidney 
cancer, ovarian cancer, glioblastoma, etc). Unfortunately, the patient sample set sizes for all 
except two cancers -- breast cancer and glioblastoma -- did not allow for accurate and 
statistically significant driver identifications for any of the used methods. We hence report results 
for these two cancers only, although a pan-cancer study is easy to conduct once sufficiently 
many samples become available. 
 
The chapter is organized as follows. Section Results contains the main results of our analysis, a 
comparison of the performance of C3 and CoMEt on breast cancer and glioblastoma data. A 
discussion of our findings and concluding remarks are given in Discussion. Section Methods 
contains a basic introduction of the principles of correlation clustering and the evaluation criteria 
used to compare C3 and CoMEt.  
 
3.2 Methods 
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3.2.1 C3 approach 
 
The basic idea behind C3 approach is correlation, an agnostic learning technique first proposed in 
Bansal et al. [117]. In the most basic form of the clustering model, one is given a set of objects 
and, for all or some pairs of objects, one is also given an assessment as to whether the objects are 
“similar” or “dissimilar”. This information is described using a complete graph with labeled 
edges: each object is represented by a vertex of the graph, and the assessments are represented by 
edges labeled with either a “+” symbol, for similar objects, or a “-”  symbol, for dissimilar 
objects. The goal is to partition the objects into clusters so that the edges within clusters are 
mostly positive and the edges between clusters are mostly negative. Unlike in many other 
clustering models, such as k-means [118], the number of clusters is not fixed ahead of time and 
finding the optimal number of clusters is part of the problem. Furthermore, the assignment of 
positive and negative edges does not have to be mutually consistent: for example, if the graph 
contains a triangle with two positive edges and one negative edge, then we must either group the 
endpoints of the negative edge together, erroneously putting a negative edge inside a cluster, 
resulting in a “negative error” or else we must group them separately, forcing one of the positive 
edges to erroneously go between clusters, resulting in a “positive error”. When a perfect 
clustering is not possible, we seek an optimal clustering: one that minimizes the total number of 
“error”. This form of correlation clustering is known to be NP-hard, but depending on the graph 
topology, various constant or logarithmic approximation guarantees exist. Bansal et al [117] also 
proposed a weighted version of the correlation-clustering problem. A more general weighted 
formulation was introduced in Chakiar et al [119] [120], and this is the formulation we 
subsequently generalize. In this model, each edge e is assigned two nonnegative weights, 𝑤f-and 𝑤fI.	A clustering incurs cost, 𝑤f- if e is placed between clusters, and incurs cost	𝑤fI	if e is placed 
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within a cluster.  
 
If no restrictions are placed on the weights 𝑤f- and 𝑤fI then it is possible to have edges with 𝑤f- = 𝑤fI = 0; these edges are effectively absent from the graph, so there is no loss of 
generality in assuming that the graph is a complete graph. Nevertheless, in order to arrive at 
problems that have efficient constant approximation algorithms, one needs to  place certain 
restrictions on 𝑤f- and 𝑤fI. The probability constraints give a natural restriction on the edge 
weights 𝑤f- = 𝑤fI = 1 for every edge e. Another restriction involves the triangle inequality, and 
one requires that  𝑤ghI = 𝑤giI + 𝑤ihI   for all distinct vertices 𝑢, 𝑣 and 𝑤. 
 
The analytic approach pursued in this work operates on the following model: genes which show 
sufficiently large mutation prevalence in cancer patients represent vertices of a complete 
connected graph whose vertices are to be clustered according to similarity criteria and weights to 
be described in detail in the next section. Note that we only use the top 5% of mutated genes in 
cancer patients, ordered by mutation frequency, as vertices. The reasoning behind our approach 
is as follows: First, low-frequency mutations require specialized statistical and network analysis 
methods which have to be developed in parallel and for which not sufficiently many patient 
samples are yet available [121], [122]; Second, even when restricting our attention to the most 
frequently mutated genes we outperform all known methods, which illustrates that one can 
significantly scale down the set of genes under consideration and at the same time improve 
identification performance. The low-frequency trimming approach results in 170 genes in 
glioblastoma (GBM) and 130 genes in breast cancer (BRCA). Although these numbers may 
appear prohibitively small given that more than a hundred cancer driver genes are reported, 
	 51	
usually only a very small number of driver genes are needed to initiate the process of 
tumorigenesis (For example, in [123], it was shown that only three driver gene mutations are 
required for the development of lung and colorectal cancers.)  
 
The weights  𝑤f- and 𝑤fI assigned to an edge e connecting two genes u and v are weighted sums 
of weights capturing driver gene features, such as mutual exclusivity, coverage strength, network 
distance and expression similarity. More precisely, the negative weights 𝑤fI are chosen to be 
relatively small if the endpoint genes describing the edge are deemed to be mutually exclusive in 
cancer patients. A small negative weight encourages placing mutually exclusive genes within the 
same cluster, as the penalty paid for placement in the same cluster is small. The positive weights 
jointly depend on the coverage, network distance and expression correlation of the endpoint 
genes: The larger the joint coverage, co-expression and inverse of the network distance of the 
endpoint genes, the larger the positive weight and the more likely the genes will end up in the 
same cluster so as to avoid paying a large cross-cluster cost. For a detailed and rigorous 
discussion of the exact method for determining clustering weights with respect to the expression, 
coverage, network and mutual exclusivity, refer to the main paper [68]. 
 
To control the size of the resulting clusters so as to discourage uninformative singleton and giant 
clusters, we developed two new correlation clustering algorithms that use cluster sizes as 
problem parameters that may be chosen by the users. These cluster size bounds also allow for 
more accurate comparison with other methods which operate with inherent cluster size 
constraints. Furthermore, as pointed out in [31], driver pathways obeying mutual exclusivity and 
coverage constraints are usually smaller than most pathways annotated in the literature. This 
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observation provides another reason for using bounded cluster sizes as well. Note that unlike in 
the aforementioned known methods, the cluster sizes have no bearing on the complexity of our 
algorithm nor on their overall approximation quality, and they may be completely removed by 
the user if so desired. 
 
The driver discovery approaches closest to C3 are Multi-Dendrix [35] and CoMEt [124] Multi-
Dendrix is an integer linear programming clustering algorithm that ensures that the genes within 
a cluster have mutation patterns that satisfy mutual exclusivity and coverage: In a nutshell, for 
any two genes in a cluster, the number of patients in which these genes are mutated at the same 
time is relatively small; in addition, a large portion of the patients has at least one mutation in 
each cluster. CoMEt uses a statistical score for mutation exclusivity that is conditioned on the 
frequency of each alteration, alleviating the inherent bias caused by frequently mutated genes. 
 
Compared to Multi-Dendrix and CoMEt, C3 uses weighted linear programming relaxation instead 
of an integer linear program which significantly improves the versatility and running time of the 
algorithm. Furthermore, the weights allow for straightforward incorporation of heterogeneous 
sources of evidence into the clustering method and the algorithm itself remains unchanged with 
the addition of new data. On the other hand, Multi-Dendrix cannot be easily adapted to new 
problem constraints. This flexibility comes at the cost of C3 providing only an approximate 
solution, but the approximate solutions exhibit large overlap with the exact solutions for a 
number of tested smaller synthetic networks. In addition, given the inherently approximate 
nature of optimization criteria, the weight selection and parametrization of both algorithms, this 
does not appear to be a significant shortcoming. Also, empirical evaluations on real data suggest 
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that the approximation algorithms produce results very close to the optimal solution.  
 
3.2.2 Clustering algorithms 
 
The classical formulation of correlation clustering does not include cluster size restrictions. On 
the other hand, all known driver identification methods operate with de facto cluster size bounds, 
as the cluster sizes govern the computational complexity of the method. For example, 
comprehensive testing of CoMEt reveals that the algorithm fails to operate beyond cluster sizes 
of 10-12. In order to perform a fair comparison, we introduce a cluster size constraint in our 
algorithm, by assuming that all clusters are of size K. Clearly, setting K equal to the number of 
vertices (genes) removes the cluster size constraint, hence our algorithm has a large flexibility in 
cluster size selection. An additional reason for choosing a restricted cluster size is that we expect 
driver genes of specific cancer types to be grouped together within clusters, and as already 
remarked, a number of recent results suggest that only a few drivers are actually present in any 
cancer type. Making the clusters excessively large would potentially lead to inclusions of 
multiple cancer type drivers in the same cluster, thereby obscuring the fine partition of the 
drivers. Nevertheless, the user of the method may choose K according to her/his own 
requirements. Yet another reason for introducing cluster sizes is to avoid the shortcomings of 
many known clustering algorithms which tend to produce non-informative “giant clusters” and 
singleton clusters. 
 
The bounded cluster size correlation clustering problem for driver gene inference may be 
formulated as follows. As already described, let K be a “hard” bound on the size of the driver 
clusters, and let the positive 𝑤-	and negative weights 𝑤I	be chosen according to a desired 
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combination of datasets, as explained in the previous section. The optimum clustering may be 
found by solving the integer linear program (ILP) below. 
 
 Minm 	(𝑤f- − 𝑤fI 1 − 𝑥f )f∈p(q)  	
 
(3.1)	
Subject	to	 𝑥gi ≤ 𝑥gv + 𝑥vi	(for	all	distinct	u, z, v	 ∈ V(G))	 (3.2)	
	 1 − 𝑥gi ≤ 𝐾	for	all	ug}i ∈ V(G)	 (3.3)	x ∈ 0,1 	for	all		𝑒 ∈ 𝐸(𝐺)	 (3.4)	
 
In this formulation, and for a fixed edge 𝑒 = 𝑢𝑣, 𝑥gi = 1	implies that 𝑢 and 𝑣should belong to 
different clusters and 𝑥gi = 0	implies that the two vertices should belong to the same cluster. 
Note that the triangle inequality (3.2) ensures that if u and z are in the same cluster and z and v 
are in the same cluster, then u and v are also in the same cluster. Any clustering of the vertices 
can be described using the variables x. For a fixed clustering, the objective function is the cost 
associated with that clustering. 
 
Solving the ILP is NP-hard. We hence relax the problem by changing the integer constraint 𝑥f ∈{0,1} to an interval constraint 𝑥f ∈ {0,1}. This relaxation leads to a classical linear program (LP), 
the solution of which may be fractional. To obtain a valid clustering, the fractional solutions 
have to be subsequently rounded to produce integer solutions. Unfortunately, known rounding 
algorithms we previously developed in [125] tend to produce very small clusters, often as small 
as single-vertex clusters that are not meaningful. For our study, we hence slightly modify the 
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algorithm by moving the cluster size constraint (3.3) from the LP to the rounding procedure (See 
original paper, Algorithm 1). Hence, the clustering algorithm involves solving (3.1) without the 
constraint 	 1 − 𝑥gi ≤ 𝐾	g}i  and then applying the rounding procedure of the rounding 
procedure. 
 
The rounding procedure is closely based on the rounding algorithm described in [119], [120] The 
idea behind the rounding algorithm is to pivot on one vertex, examine its closest neighbors, 
where closeness is governed by the value of the output variables 𝑥fof the LP, and partition large 
neighborhoods if needed to get clusters of size at most K + 1. Given that the parameter α is set to 
2/7 and given that the weights obey the following constraints: 
• 𝑤f- ≤ 1 For each edge e 
• 𝑤f- + 𝑤fI ≤ 1 For each edge e 
 
The above inequalities were addressed as described in the previous section, and we remind the 
reader that they were imposed on the weights through proper normalization. Note that we only 
used high frequency mutations for our clustering problem, and hence did not encounter any 
computational issues with the LP solvers. On the other hand, if one were touse all 25,000 genes 
in the analysis, the LP solver implemented in Gurobi (https://www.gurobi.com/) would 
inevitably break down due to the large number of constraints, which is quadratic in the number 
of genes. In this case, a much simpler scalable solution is to use  approximate LP solvers, akin to 
those described in [126].The approximate solver is guaranteed to produce a solution that does not 
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exceed the LP solution by more than a factor 1 + 𝜀, for some small value of 𝜀, by using gradient 
descent methods that are highly scalable. 
 
3.2.3 Evaluation methods 
 
We evaluated the performance of both C3 and CoMEt in terms of their ability to detect mutually 
exclusive, high-coverage, and biologically relevant gene clusters. At this point, it is important to 
observe that the inference and evaluation strategies may appear to involve circular arguments: 
Mutual exclusivity, coverage and network distance, used to predict the clusters, are also used to 
evaluate the performance of the clustering method. But this is clearly not the case, as mutual 
exclusivity, coverage and network distance are optimization constraints, and one always needs to 
test the quality of a (approximate) solution to an optimization problem based on how well the 
constraints are accounted for. Other driver discovery tools, such as CoMEt, use the same 
constraint modeling and evaluation criteria. Furthermore, we added one more evaluation criteria, 
related to biological significance and pathway enrichment analysis, which is independent on the 
optimization criteria. As will be shown in the subsequent section, this evaluation criterion 
confirms the quality of the C3 analysis for cancer driver gene inference and its improvements 
over CoMEt. 
 
We ran both the C3 and CoMEt methods using mutation and CNA data collected from TCGA, 
pertaining to breast cancer (BRCA) [44] and glioblastoma (GBM) [77]. In addition to GBM and 
BRCA, we also considered kidney cancer (KIRC) and ovarian cancer (OV), but the available 
patient data appeared limited at this stage to allow for statistically significant and comprehensive 
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results. We accessed the TCGA provisional data using the cBioPortal platform [127] on August 
14, 2015.  
 
We ran both methods using the same alteration dataset.  We evaluated both point mutations and 
indels, and for CNAs, we used the GISTIC thresholds [128] of -1 and 3 as our cut-offs (as 
already pointed out in the previous section).  To focus on mutations with high frequency, we 
only selected genes in the top 95 percentile of alteration frequencies, thereby obtaining 130 
genes spanning 959 patient samples in BRCA and 170 genes spanning 291 patient samples in 
GBM. 
 
To test the effects of cluster sizes and the quality of our results, we ran both C3 and CoMEt to 
find clusters of sizes upper bounded by 5, 6, 7, 10, and 15. As already pointed out, larger cluster 
sizes are easily accommodated for C3, but since CoMEt failed to produce solutions for clusters of 
sizes roughly greater than ten, we restricted our attention to the aforementioned range of values. 
Due to the fact that correlation clustering and CoMEt will cluster all genes in a dataset, and 
hence produce a partition of the gene set, a large number of clusters will contain neutral 
mutations only and will hence have no biological significance. This is why we only compared 
the top ten most mutually exclusive gene sets generated by C3 with those of CoMEt. 
 
We ran CoMEt with 1,000 iterations each and 3 initialization points to ensure both timely and 
consistent runs. For C3, we ran the C3 clustering method for all combinations of weights 𝑤.,𝑤, 𝑤 ∈ {0,0.25,0.5,0.75,1} that satisfy 𝑤. + 𝑤 + 𝑤 = 1	but selected to report only 
results for the weight parameters 𝑤. = 0.167 (coverage), 𝑤 = 0.333 (network information) and 
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𝑤 = 0.5  (expression data). Our choice is governed by the fact that coverage seems to be a 
biologically much less important criterion then network information or expression. Hence, high 
weights for expression and network information increase the ability of the C3 algorithm to detect 
biologically significant clusters. Furthermore, the patient coverage criteria appear to be less 
relevant than pathway coverage and some other coverage properties that have not been explicitly 
investigated in the literature. Nevertheless, we observe that the choice of the weights may be 
completely governed by the user, and that the increase in one weight may produce better results 
in one performance category while reducing the performance in another category.  
We used four statistical methods to assess the performance of the algorithms which reflect both 
the statistical and biological significance of the clusters found. 
 
Mutual Exclusivity: To evaluate the degree of mutual exclusivity in a cluster’ we performed a 
Fisher's exact tests [129] for each pair of genes in ’he cluster. The Fisher's exact test uses a 
hypergeometric distribution to calculate the probability of observing a 2	×	2 contingency table of 
a total of n samples, with a samples that have an alteration in two genes (say, 𝑔'	and 𝑔(), 𝑏	samples with an alteration in gene	𝑔' only, and 𝑐 samples with an alteration in gene 𝑔(	only. If 
d is the number of samples with no alteration in either gene, then the probability of co-mutation 
is evaluated according to 
 
𝑃 𝑔', 𝑔( = - -C-  (3.5)	
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We also evaluated the overall exclusivity of a cluster as the median value of each 
pairwise exclusivity test, for each pair of genes 𝑔', 𝑔( in the netwo’k. The pairwise Fisher's 
method has also been used by the Mutex suite to establish mutual exclusivity [130]. However, 
because the context that the Fisher's exact test is used as an evaluation rather than as a discovery 
tool, we used the median pairwise p-value rather than the maximum p-value to get a better sense 
of the overall exclusivity of genes within a cluster. It is also important to note that while CoMEt 
has a built-in method that generalizes the exclusivity test to a 2k contingency table for a cluster 
size 𝑘 ≥ 2	the exponential size of their test set makes evaluation for large cluster sizes 
computationally impractical. An alternative test for overall mutual exclusivity is a permutation 
test, as implemented by MEMo, which compares the exclusivity of a gene set by sampling 
random gene sets and patients with multiple alterations. 
 
Coverage: To compare and evaluate the overall coverage of a cluster found by C3 or CoMEt, we 
calculated and reported the proportion of patients with at least one alteration in a gene belonging 
to the given cluster. 
 
Network Clustering: We performed an additional pathway analysis for the potential cancer gene 
drivers. As pointed out in the previous section, driver genes tend to be, on average, closer to each 
other in a pathway compared to randomly selected genes. Our tests involved assessing the 
shortest network distance of genes within the discovered clusters. We remind the readers that the 
distances were e’aluated using Dijkstra's Algorithm on 8,726 genes from [29]. 
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Biological Significance: In addition to testing the quality of the algorithm in terms of optimizing 
mutual exclusivity and coverage, we also investigated the biological significance of the C3 and 
CoMEt methods from the perspective of gene discovery and pathway analysis. Although there is 
no overarching gold standard to determine biological significance, a commonly accepted metric 
employed by MEMo, Dendrix, Mutex, CoMEt and other similar tools is to count the number of 
known driver genes found within the best clusters according to the given criteria. These clusters 
usually contain known driver genes. To determine the driver gene-based biological significance, 
we calculated the proportion of drivers found in the ten most mutually-exclusive C3and CoMEt 
clusters using a comprehensive, curated list of known drivers from the CGC. 
 
It is important to point out that while the four test benchmarks we introduced are a reliable way 
to test the optimization quality and performance of CoMEt and C3, no perfect benchmark exists 
for detecting mutually exclusive and biologically significant genes clusters. The hope is that 
multiple evaluation methods taken together may provide a better understanding of which 
methods outperform others in a given parameter and criteria setting. 
 
3.3 Results 
 
In what follows, we demonstrate that C3outperforms CoMEt in almost all of the aforementioned 
benchmarking criteria, or more precisely, for three out of the four chosen criteria. This is 
achieved without any special parameter tuning or optimization. As a rule of thumb, C3 can be 
made to outperform CoMEt in any chosen single, pair of triple of criteria by adjusting the 
weights. This observation may be explained by the fact that the weights trade off the strengths of 
different modeling assumptions. We supplement our statistical analysis with a discussion of the 
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biological relevance of our findings, and explore the role of the new potential drivers found by 
C3 within their driver gene communities. In particular, we discuss the significance of large 
mutually exclusive clusters that cannot be recovered by other methods. Recall that we restrict our 
attention to the ten best performing clusters according to mutual exclusivity, as this approach 
was used in the original evaluation process of the CoMEt algorithm. 
 
3.3.1 Performance evaluation 
 
The results of our extensive comparison between C3 and CoMEt, regarding mutual exclusivity, 
coverage, driver identification, and pathway-level evaluation, are shown in Figure 10. Both 
algorithms were tested on the same server with a 256GB RAM memory. Both methods ran 
uninterruptedly when the cluster sizes were constrained 𝑘 = 5, 6, 7,	10. CoMEt reported segfault 
memory errors for 𝑘 = 15, and for this case, only C3 was benchmarked. 
 
To assess the biological significance of the two methods in terms of their ability to cluster high-
impact drivers from the CGC repository together, we compared the results of C3 and CoMEt both 
to each other and to a “baseline” value equal to the average proportion of drivers in the ten most 
mutually-exclusive clusters found, in this case 0.067, using uniform random sampling of genes 
(see Figure 10A).  
 
In BRCA, we found that C3 detected a median driver proportion of 0.160 and CoMEt detected a 
median driver proportion of 0.117 in the top ten clusters. C3 outperformed CoMEt for each 
cluster size. We also used a Mann-Whitney Rank Sum test [131] to compare the overall 
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performance of the algorithms with respect to mutual exclusivity, for all cluster sizes. We chose 
a rank-sum test because it is unclear that the drivers are following a normal distribution due to 
the small amount of data points available. The results show that C3 outperforms CoMEt (p-value 
of 0.0079) in terms of amount of drivers in clusters. C3 also outperforms CoMEt on GBM, with a 
median proportion of drivers per cluster equal to 0.170, compared to a 0.12 proportion of drivers 
per cluster found by CoMEt. This finding holds for every cluster size, with a rank-sum test p-
value of 0.0361. Both methods succeed in finding biologically significant drivers within clusters 
exhibiting high mutual exclusivity, and both methods significantly outperform the expected 
number of drivers per cluster in the random setting p-value 1.594e-5 and p-value 1.312e-3 for C3 
and CoMEt, respectively). 
 
We next tested the clusters found by each method based on their mutual exclusivity (see Figure 
10B). To do so, we used the previously described pairwise Fisher's exact test to obtain a p-value 
for each of the top ten clusters of the two methods. For better visualization, we performed a 
negative log transform on the p-values, and plotted the transformed p-value distribution. Hence, 
in this system, larger values indicate more mutually exclusivity.  
 
We again used a Mann-Whitney rank-sum test to evaluate the performance of C3 and CoMEt. 
For BRCA, one can see that while both methods have significant median exclusivity values (p = 
7.541e-6 for C3 and p = 3.337e-4 for CoMEt, C3 has an overall more significant p-values for 
each cluster size. The median p-value of C3 for each cluster size is lower than its CoMEt 
counterpart except for the case k=10. However, C3 does have superior performance overall with a 
rank-sum p-value of p = 4.020e-4. For GBM, the median exclusivity results are not as strong as 
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for the BRCA set, for both the C3 and CoMEt method. C3 has a median p-value of 0.3095 as 
opposed to CoMEt’s 0.5022. The general drop in significance may be attributed to a lower 
c’nfidence of the Fisher's test due to a small number of samples available; recall that the GBM 
set involved 291 samples, compared to 959 BRCA samples. This indicates that one should look 
at individual significant clusters to evaluate mutual exclusivity. Even for the reduced median p-
value regime, C3 outperforms CoMEt in significance, having lower median p-values for each 
cluster size. Overall, the C3 p-values are consistently and significantly lower than those produced 
by CoMEt for mutual exclusivity (the rank-sum test p-value equals 0.04401). 
 
The results of the coverage tests are depicted in Figure 10C. In the coverage benchmark, CoMEt 
outperforms C3 for GBM, but neither method outperforms the other for BRCA. In BRCA, both 
methods show comparable performance, with a median result for the fraction of samples covered 
equal to 0.5505 for C3, and 0.5662 for CoMEt. This rather poor performance of both methods is 
observed for all values of k, with no p-value based on Student's T-test [132] being less than 0.05. 
The largest difference in coverage recorded for the two methods is present for 𝑘 = 6. In 
conclusion, there appears to be no statistical difference between C3 and CoMEt in terms of 
BRCA coverage percentage (p-value of 0.5127). In GBM, the median p-value for coverage 
difference is more pronounced. The median coverage of C3 is 0.632 and the median coverage of 
CoMEt is 0.696. CoMEt finds significantly higher-coverage cluste’s according to Student's T-
test, with p-value 0.0345, and the most pronounced coverage percentage differences exist for 
small values of k (0.3745 vs. 0.6495 for 𝑘 = 5 C3 and CoMEt, respectively). 
It is also important to note the wide distribution of coverage score values produced by C3 for 
small k; the IQR (Interquartile range) value is roughly 0.35 for 𝑘 = 6. The most likely reason 
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behind this result is that our test weights were chosen to boost the relevance of mutual-
exclusivity and biological significance rather than coverage. Mutual exclusivity accounts for 
100% of the negative weights of edges, while coverage accounts for only 16.7% of the positive 
weights. We justify this weight choice by the fact that it leads to multiple significant cluster 
discovery and with our assumption that coverage is a less significant driver property compared to 
mutual exclusivity. We also point out that it appears that a biologically more relevant coverage 
constraint is pathway coverage, rather than patient sample coverage. Another setting in which we 
analyzed C3 and CoMEt involves pairwise distances of drivers in the network (see Figure 10D). 
Here, we calculated the average pairwise distance between all pairs of genes clustered together. 
We then used Student's T-test to determine the statistical significance of this value. We also 
compared the values for both algorithms based on 1000 randomly selected genes by using a 
permutation test. For BRCA, we found no significant performance difference between the two 
methods in terms of the average pairwise distance: 3.110 for C3 and 3.070 for CoMEt, with a p-
value of 0.9330. In GBM, C3 showed a smaller average pairwise distance of 2.908 compared to 
CoMEt's 3.097. This difference is statistically significant, with a p-value of 0.0379. The small 
average network distance results of C3 for GBM, coupled with the low coverage, leads to the 
conclusion that C3 favors niche, exclusive clusters in biologically relevant cancer pathways. 
Hence, the method may be useful for discovering specific molecular cancer subtypes. Both 
methods had an average pairwise distance well below the permutation benchmark of 3.903: the 
p-values of both C3 and CoMEt were less than 2e-16 for both cancers. 
 
In conclusion, from our detailed evaluation we conclude that although C3 does not 
simultaneously outperform CoMEt with respect to all four evaluation criteria, but only three of 
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them (which already represents a significant advantage), the C3 performance indicates a strong 
overall propensity to select biologically more relevant and more mutually exclusive clusters, 
with a higher degree of flexibility compared to CoMEt. 
 
3.3.2 Discovering potential driver pathways  
 
We examine next the potential of the C3 algorithm to detect clusters whose genes may be new 
candidate cancer drivers. We focus our search on clusters that contain biologically significant 
driver genes and known biological network interactions, and exhibit high mutual exclusivity and 
coverage. At the same time, we only consider the large cluster size regime, as results in this 
domain have not been previously reported in the literature and as they offer many new 
interesting insights. Two examples of our analysis are shown in Figure 11 and Figure 12. 
 
In BRCA, one candidate cluster with several potential novel driver genes is the cluster 
containing PTEN, HUWE1, CNTNAP2, GRID2, CACNA1B, CYSLTR2, MYH1 depicted in Figure 
11. The genes in the candidate cluster are mutually exclusive (p-value 0.0084). The genomic 
landscape of this cluster is dominated primarily by mutations in PTEN and HUWE1, and 
secondarily by homozygous deletions in PTEN and CYSLTR2. The most frequently altered gene 
in this set is a common driver gene PTEN, a tumor suppressor gene that negatively regulates the 
AKT/PKB apoptosis pathway [133]. The remaining six genes in the cluster are potential driver 
candidates HUWE1 is a part of the Mule multidomain complex of the HECT domain family of 
E3 ubiquitin ligases responsible for apoptosis suppression, DNA damage repair, and 
transcriptional regulation [134]. CNTNAP2 is a neurexin protein with functions in cell-to-cell 
adhesion and an epidermal growth factor and was found to be hypomethylated in breast cancer 
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cell lines [135]. Hypomethylation and the association with epidermal growth factors, coupled 
with a large number of amplifications in the alteration landscape of CNTNAP2 suggest potential 
oncogenic functions of the gene. GRID2 is an ionotropic glutamate receptor that is frequently 
deleted in lymphoma [136]. CACNA1B codes for a N-type calcium channel which is responsible 
for calcium influx. Defects in the calcium influx channel can lead to alteration in the apoptosis, 
proliferation, migration and invasion pathways of breast cancer [137]. CYSLTR2 is a 
proinflammatory cysteinyl leukotriene receptor that plays a role in cancer cell differentiation and 
is associated with breast cancer survival rates [138]. MYH1 is a myosin heavy chain protein that 
plays a role in cell signaling and pro-apotosis pathways. 
 
Perhaps more important than the propensity of each individual gene to be a driver is the 
collective interaction pattern of the seven genes in the cluster in a cancer pathway. From Figure 
11, it is clear that the each gene in the cluster interacts with each other in a tightly-connected 
community with no gene more than three nodes away when plotted in the network, using the 
cBioPortal visualization tool [127]. The seven genes in the cluster PTEN, HUWE1, CNTNAP2, 
GRID2, CACNA1B, CYSLTR2, MYH1 are strong candidates to define a novel driver pathway.  
 
This conclusion is reinforced by the presence of high impact common drivers TP53, MYC, AKT, 
and PIK3R1 which define several important cancer pathways such as apoptosis, DNA repair, and 
cell cycle arrest [139], [140].We also examined a cluster containing potential cancer drivers 
relevant for GBM. In GBM, we found a cluster of size 10 with four known drivers and many 
potential drivers. The cluster includes GLI1, WNT2, BRAF, PLCG1, FAS, CREBBP, BRCA2, 
GLI2, PIK3R5, VAMP3 (see Figure 12). This large cluster has a p-value of 0.0901 in terms of 
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mutual exclusivity, which is actually low as compared to other GBM clusters. The cluster also 
contains several important driver genes such as WNT2, BRAF, BRCA2 and CREBBP which 
encompass pathways such as sonic hedgehog signaling, cell fate determination, cell growth and 
apoptosis, checkpoint activation, and DNA repair. Additionally, six out of the ten members are 
within the same compact network community GLI1, PLCG1, FAS, CREBBP, BRCA2, PIK3R5. 
Of these six genes, GLI1 and GLI2 are hedgehog signaling genes that are common and first 
isolated in glioblastoma. These genes are responsible for cell differentiation and stem cell self-
renewal [141]. PLCG1 is involved in intracellular transduction of receptor-mediated tyrosine 
kinase activators, and it has been classified as a biomarker in GBM [142]. FAS is a cell surface 
receptor that mediates apoptosis. FAS is known as a histological hallmark of GBM, affecting 
both apoptosis and necrosis factors [143]. Finally, PIK3R5 is a subunit of phosphatidylinositol 3-
kinases who together have important effects on cell growth, proliferation, differentiation, 
motility, survival and intracellular trafficking.  
 
3.4 Discussion 
  
We described a novel method, termed C3, which has the potential to precisely and efficiently 
identify clusters of gene modules with mutually exclusive mutation patterns. The C3 algorithm 
uses large-scale cancer genomics datasets which are pre-processed to yield parameters governing 
novel constrained correlation clustering techniques. The optimization criteria used in clustering 
include patterns of mutual exclusivity of mutations, patient sample coverage, and network driver 
concentration. 
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There are several major advancements of our method when compared to previously known 
approaches. Unlike methods that use randomized approaches without the guarantee that multiple 
runs of the methods on the same data will produce compatible results (such as CoMEt), C3 is 
“consistent” in so far that by running the same LP solver, the same results will be generated. 
Also, C3 has computational complexity that does not depend on the chosen cluster sizes, and is 
hence much more appropriate for large cluster problems than other methods. Furthermore, it 
partitions the gene set and hence creates clusters covering all genes used in the analysis, although 
it may also be adapted to accommodate overlapping clusters. This is in contrast with the results 
produced by other methods that tend to identify only a small number of modules with limited 
number of genes. 
 
None of the previous methods were able to identify clusters utilizing different sources of 
information via a weighting mechanism. This is important because it gives us flexibility to focus 
more on certain aspects based on the analysis. For example, we can focus more on mutual 
exclusivity instead of coverage to identify clusters specific to a group of samples which may 
facilitate the discovery of subtype-specific modules. 
 
By addressing the above challenges, we believe our new method C3 represents a unique tool to 
efficiently and reliably identify mutation patterns and driver pathways in large-scale cancer 
genomics studies. 
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FIGURES
Figure 8: Histogram of shortest distances between randomly selected genes and driver genes in 
the network. 
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Figure 9: A workflow of C3 displaying heterogeneous data sources converted into different 
clustering weights. 
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Figure 10: A comparative analysis of C3 (Red) and CoMEt (Blue) based on four evaluation 
criteria. We used five cluster sizes (5,6,7,10, and 15) that index the x-axis in each benchmark 
test. (A) depicts the results based on the driver gene evaluation criteria. The y-axis represents the 
proportion of drivers found by each method, contained within the best ten clusters found. The 
purple line represents the expected value of drivers detected if clusters are randomly selected.  
(B) shows the pairwise mutual exclusivity of each run. The y-axis represents the negative log
transform of the mutual exclusive p-value such that larger values are more mutually exclusive 
than smaller ones. The boxplots illustrate the distribution of exclusivity results concerning each 
of the top ten individual clusters for C3 and CoMEt. (C) shows the distribution of coverage, 
measured by proportion of samples with at least one alteration in a given cluster (the y-axis). The 
boxplot illustrates the distribution of coverage results for individual top ten cluster results.  
(D) includes the network connectivity results of C3  and CoMEt. The y-axis measures the average
pairwise network distance between all genes in a cluster, and the distribution of each cluster is 
shown in the boxplot. The purple line represents the average pairwise distance of random 
clusters. 
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Figure 11: A cluster of potential driver genes inferred from BRCA. (A) shows the alteration 
landscape of the cluster, with blue representing mutation events, red representing copy number 
deletions, and green representing copy number amplifications. (B) represents a known 
subnetwork which contains 6 genes (out of 7) in (A). The more intense the red, the higher the 
alteration frequency of the gene. Nodes highlighted in black represent driver candidates 
identified by C3 within a small subnetwork. Edges are depicted in black if there exists a direct 
interaction between two genes. Green edges represent an interaction that undergoes a protein 
state change. Purple edges are other interactions.  
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Figure 12: A cluster of potential driver genes inferred from BRCA. (A) shows the alteration 
landscape of the cluster, with blue representing mutation events, red representing copy number 
deletions, and green representing copy number amplifications. (B) represents a known 
subnetwork which contains 6 genes (out of 7) in (A). The more intense the red, the higher the 
alteration frequency of the gene. Nodes highlighted in black represent driver candidates 
identified by C3 within a small subnetwork. Edges are depicted in black if there exists a direct 
interaction between two genes. Green edges represent an interaction that undergoes a protein 
state change. Purple edges are other interactions.  
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4.1 Introduction 
The practice of oncology continually faces the challenge of matching cancer patients with an 
optimal treatment regimen. The challenge is especially daunting in cancer chemotherapy, where 
the success rate of cancer compounds meeting FDA approval for effectiveness and safety is a 
mere 13.4% [144]. The marginal success rate of cancer therapeutics is likely due to the enormous 
complexity of the disease mechanism of cancer coupled with an inability to properly match the 
drug to the patients where it would have the largest positive impact [145]. Cancer is a disease of 
the genome is driven by unique, patient specific, alterations that affect major pathways in 
growth, survival, and division [52]. One strategy that can be employed by physicians is to target 
the genome by prescribing targeted therapies in which treatments are tailor-made to individual 
patients that specifically target perturbations in the patient’s genome [146].  In recent years, 
computational methods have been utilized to define and process the enormous swaths of data 
needed to identify the patient’s genomic perturbations and predict the drug targets that work best 
for the patient.  
The problem of developing computational tools to model drug treatment presents a set of major 
challenges. The interaction between cancer drugs and cancer cell lines is complex and not well 
not well understood in many cases [51]. Even though databases such as the Drug Gene 
Interaction Database (DGIdb) [147] have mapped out many of the interactions between drugs 
and the genome, the database is far from complete and many drug interactions with the genome 
and drug interactions with other drugs are unknown [148]. The context of the data is also 
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imperfect. The majority of data available for drug response analysis comes from cell lines 
compendiums such as The Genomics of Drug Sensitivity of Cancer [53] and the Cancer Cell 
Line Encyclopedia [54]. However, experimental procedure differences between the major cell 
line compendiums have shown inconsistent drug response when the same drug is treated with the 
same cell line [59] Additionally, cancer tumors do not reside in a closed system. Tumors react 
closely with normal cells and the patient’s environment [60]. This may limit the scope of many 
cell line-based studies of drug response. 
Many pioneering studies concerning drug response have been made using cell lines. One of them 
was the NCI’s DREAM7 initiative. [149]. The DREAM7 project was a community driven 
project where teams would predict the drug response of “hidden” BRCA cell lines using RNA-
seq data from training cell lines. The winning methods in DREAM7 were a Bayesian kernel 
multitask model and an integrated Random Forest method. Since DREAM7, several 
contemporary methods have been developed predict the drug response in cancer cell lines. Such 
studies include the machine learning methods using GDSC and CCLE datasets such as SVM 
with Recursive Feature Elimination binary prediction approach in calculating acute drug 
response [55] and CancerDP, another drug prioritization method based on SVM with F-stepping 
feature selection [56]. The authors of [57] implemented a linear method which calculated the 
drug response of Lymphoblastic cell lines (LCL). An ensemble method utilizing the integration 
of multiple machine learning methods, PGM, was especially unique in that it simultaneously 
modeled chemical and cell line information together to make a prediction [150]. Most recently, a 
comprehensive study unconverted a list of features corresponding to Cancer Functional Events 
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(CFEs) and used those features to accurately predict the drug response of over 1000 human cell 
lines [58]. 
One important limitation of the cell line studies is that the extent that application of in vitro 
studies extends to conclusions of the treatment paradigm in real patients is still unknown [151]. 
Therefore, several studies in drug response have shifted focus from cell line data models to 
models based on real patient data. Many of these methods utilize patient data from The Cancer 
Genome Atlas [152]. The authors of [61] utilized a linear Ridge-Regression model to bridge the 
gap using in vitro gene expression models to make predictions in vivo. While gene expression 
models have shown a degree of success, gene expression models alone have been found to be 
insufficient in predicting drug response in some cancers [62]. The IntOGen platform also has a 
tool that assigns drugs to patients based on their proximity to the driver gene in a cancer network 
[63]. The identification of targetable genes was expanded using the EMD model, which 
identified a list of candidate drivers using integrated gene expression, mutation, copy number 
and network information with potential drug targets for the drivers [64]. Another method 
GOPredict [63] integrates both genomic and pathway data to provide a ranked drug list of 
potential targets [65]. While these methods provide a starting point in computational drug 
prediction, none of these the methods evaluate their approach using recorded actual drug 
response or the actual drugs that were prescribed to the patient. Rather, these methods rely on 
indirect comparisons of potential drug targets, or they only look at evaluating a few select 
patients, drug target, and drug response combinations. 
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Recently, the authors of [66] have presented a method that predicts the clinical response of a 
drug directly from in vivo molecular signature data. The authors of [66] used an ElasticNet 
Regression classifier to predict a physician-coded drug response on cancer patients using data 
from one type of feature ranging from mRNA or miRNA expression, methylation, or copy 
number. However, while the approach was new, it was also hindered by several limitations. Most 
drug-specific models in [66] exhibited poor performance due to lack of sophisticated feature 
selection and filtering coupled with the limitation of a small n large p (large number of features 
compared to a small number of samples) and the inability to build models using multiple types of 
features. 
To address the limitations of previous methods, we developed a novel drug response prediction 
and drug prioritization algorithm called Scattershot. Scattershot models the problem of drug 
response and drug recommendation as a multilabel machine learning problem in which multiple 
response variables (labels) are predicted simultaneously while accounting for the interactions 
among the labels [69] where we develop ensemble classifiers from multiple genomic sources 
such as mutation, expression, copy number, and pathway-level information as well as clinical 
variables. Scattershot uses the multilabel framework to build binary classifiers that predict the 
drug response of an individual drug while at the same time, aggregating the results of multiple 
pairwise binary classifiers comparing pairs of drugs in a drug list to prioritize the drug rankings. 
Scattershot’s integrated approach has outperformed previous methods in predicting drug 
response in actual patient data, and its novel recommender has consistently ranked actual 
prescribed drugs high in a large majority of patients. 
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4.2 Results 
4.2.1 Method overview 
Here we provide an overview of the Scattershot algorithm. Detailed method description is in the 
Methods section. Figure 13 provides an overview of the whole method. Scattershot is a 
multilabel machine learning algorithm that predicts multiple responses (a list of drugs) with two 
modes: 1) single drug mode (SDM) and 2) pairwise recommendation mode (PRM). Single drug 
mode uses a classifier to predict the clinical response of a single drug in a group of test patients. 
Pairwise recommendation mode is a multilabel classification method that ranks a list of drugs in 
a test patient ordered from most to least likely to respond by simplifying the multilabel problem 
into a combination of binary label classifiers and rank-aggregating the binary classifiers to 
provide the final rank list.  The first step of Scattershot is feature selection. Scattershot assembles 
features from multiple different sources. These sources include genomic features from 
expression, mutation and copy number information, drug target interaction data in a human gene 
pathway context as well as other user input features such as clinical information. The feature 
selection step for genomic information includes only genomic features that have been proven to 
have a biological and clinical significance to drive cancer. The significant cancer gene filter was 
assembled from 3 sources: 1) DawnRank [67] 2) Cancer Functional Events (CFEs) [58] and 3) 
the cancer gene census [101]. The second step in the Scattershot process is the machine learning 
classifier. This was done as a binary classifier using Random Forest with recursive feature 
elimination, RFE to further whittle down extraneous features. The response variable for the 
Random Forest differs in the single drug mode and pairwise recommendation mode. In SDM, the 
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binary classifier calculates effectiveness (did the drug work?) for a test patient while in pairwise 
recommendation mode, the binary classifier predicts a preference between any two drugs (which 
of the two drugs would work better?). For Scattershot in PRM, multiple binary classifiers 
comparing all combinations of any two drugs were rank-aggregated in a FAS-pivot algorithm to 
identify a preference list using the multi-label learning framework.  
We ran Scattershot on two TCGA drug response datasets: a Pan-Cancer dataset consisting of 
1508 samples, and a breast cancer dataset consisting of 647 samples. Within each dataset, we 
performed two analyses: a single drug mode analysis to quantify the drug response of a single 
drug, and a pairwise recommendation mode to rank-order potential drug treatments for any given 
patient. The single drug mode was done on 4 breast cancer drugs and 7 additional Pan-Cancer 
drugs. We limited our drug response information to the same information used in [66] to 
compare the performance of the two methods as closely as possible. We then used the results of 
the classifier to determine whether our drug prescription is associated with any clinical outcomes 
such as survival. The PRM analyses ranked a list of 11 breast cancer drugs and 22 Pan-Cancer 
drugs for each patient, and we visualized the data in terms of its pairwise classifier performance, 
overall rank precision performance, and its ability to recommend novel and/or infrequently 
prescribed drugs. 
4.2.2 Scattershot accurately predicts drug response for single drugs 
We first used Scattershot in SDM to build a drug response classifier for each drug to evaluate the 
overall performance of the model. We limited our results to drugs with physician-coded response 
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in at least 5% of prescribed patients, leaving 4 breast cancer drugs and 11 Pan-Cancer drugs 
(including the 4 breast cancer drugs). We chose 5% because it is the smallest cutoff in all 
analyses where the number of cross-validation samples n will be larger than the average number 
of features p, which avoids the small n large p problem [153]. At a 5% cutoff in breast cancer, 
for example, a drug has to have at least 30 physician coded responses . The average number of 
features in a breast cancer single drug mode is 24.25. We evaluated our method using standard 
binary metrics in sensitivity, specificity, AUC, and accuracy. We also used at the Cohen’s kappa 
coefficient which evaluates the model performance by comparing to a chance agreement. The 
kappa statistic is defined as: (𝑝 − 𝑝f)/(1 − 𝑝f), where 𝑝f is the expected probability that the 
classifier will output the result by chance and 𝑝 is the observed probability that the classifier 
will output the result. In other words, given a 2	×	2 confusion comparing the classifier 
predictions with the true results. 
(+) (-) 
(+) 𝑎 b 
(-) c d 
𝑝	is the observed accuracy of the confusion matrix (𝑎 + 𝑑)/(𝑎 + 𝑏 + 𝑐 + 𝑑) while 𝑝f is the 
expected probability of random agreement, calculated by the sum of the marginal probabilities (𝑚𝑎𝑟𝑔𝑖𝑛𝑎𝑙 + 𝑚𝑎𝑟𝑔𝑖𝑛𝑎𝑙)/(𝑎 + 𝑏 + 𝑐 + 𝑑) where	𝑚𝑎𝑟𝑔𝑖𝑛𝑎𝑙 = ( 𝑎 + 𝑏 𝑎 + 𝑐 )/(𝑎 + 𝑏 +𝑐 + 𝑑) and 𝑚𝑎𝑟𝑔𝑖𝑛𝑎𝑙 = ( 𝑑 + 𝑐 𝑑 + 𝑏 )/(𝑎 + 𝑏 + 𝑐 + 𝑑). 
A kappa statistic is similar to a correlation measure and the output ranges from -1 to 1 where 1 
indicates a perfect classification in which all predictions made by the model are not by chance or 
81	
guessing, -1 indicates that the classifier built on random guessing always performs better than the 
model, and 0 indicates no distinguishable difference between the model and the result by chance 
or guessing. We interpret the kappa statistic using Landis and Koch’s approach where 0-0.2 is 
“weak”, 0.2-0.4 is “fair”, 0.4-0.6 is “moderate”, 0.6-0.8 is “substantial”, and 0.8 to 1 is “almost 
perfect” [154]. 
Figure 14A shows the mean AUC performance of three of the drug response classifiers in BRCA 
from 10-fold cross validation, and reported the median value from the classifer. We excluded 
Doxorubicin because it had highly skewed class imbalances where <10% of the data was a 
disease state, which did not yield enough data points to accurately assess the performance of the 
Doxorubicin classifier. Hence, we observed excellent performances of Doxorubicin accuracy of 
91%, AUC of 90%, but a poor Doxorubicin kappa of 0.02. The remaining single drug classifiers 
in breast cancer had more reliable results, with an 88.3% AUC for Anastrozole and a “moderate” 
kappa of 0.463, a 94.1% AUC for Tamoxifen and a “fair” kappa of 0.384, and an 81.8% AUC 
for Paclitaxel and a “moderate” kappa of 0.435.  
In Figure 14C, we extended our Scattershot single drug mode classifiers of the Pan-Cancer 
dataset. With many more samples, the Pan-Cancer dataset allows us to evaluate more drugs than 
the BRCA dataset alone. The median of AUC of the classifiers is 86.1% with a median kappa of 
0.277.  The Pan-Cancer results provide analysis of drugs that we were not able to categorize in 
the breast cancer analysis due to lack of data. This includes Cisplatin (AUC: 90.9%), Carboplatin 
(AUC: 82.0%), Cyclophosphalamide (AUC: 85.5%), Doxorubicin (AUC: 86.7%), Gemcitabine 
(AUC: 76.5%), and Temzolomide (AUC: 74.3%). We next determined whether or not the 
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patients that we predict to respond to a certain drug would actually have a clinically significant 
response. We used survival analysis in breast cancer patients to determine whether patients with 
a Scattershot predicted positive response to Anastrozole, Paclitaxel, or Tamoxifen treatment 
would have a different clinical outcome in terms of survival (see Figure 14B). We looked at 
TCGA clinical 5-year survival data. The significance of survival was calculated using a chi-
squared test, and we found that the patients predicted to respond to Anastrozole and Tamoxifen 
exhibited a statistically higher survival rate than patients expected to respond poorly to these 
drugs (p-value 0.012 and p-value < 2e-16, respectively). No significant difference in survival 
was found in Paclitaxel (p-value 0.516).  
Scattershot identifies patients in which Anastrozole and Tamoxifen administration significantly 
improve survival. Both Anastrozole and Tamoxifen inhibit aromatase, an enzyme that 
synthesizes estrogen. Unsurprisingly, Aromatase Inhibitors are often prescribed for ER+ breast 
cancer patients [155]. We examined features of the Anastrozole and Tamoxifen classifier to 
identify which features in the model are the most important survival indicators in ER+ breast 
cancer. Tamoxifen has the ESR2 drug target as its fourth most common feature. The ESR2 gene 
codes for Estrogen Receptor beta, a key pathway in ER+ breast cancer [156]. Clinically, ESR2 is 
widely targeted in BRCA, and the ESR2 molecular marker is highly correlated with survival 
[157]. Anastrozole is another drug that serves as a survival predictor . In  Scattershot’s 
Anastrozole classifier, the second most important feature is CTNNB1.  CTNNB1 coordinates cell-
to-cell adhesion and gene transcription, and it promotes the Wnt signaling pathway, a prominent 
signaling pathway which controls cell fate specification, cell migration, and G1/S cell 
proliferation. CTNNB1 and the Wnt signaling pathway is commonly perturbed in ER+ breast 
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cancer [158]. Like with ESR2, CTNNB1 is also widely targeted and it is strongly associated with 
BRCA survival [159].  Survival markers such as ESR2 and CTNNB1 in ER+ breast cancer 
explain how Scattershot identifies patients where Tamoxifen and Anastrozole can be 
administered to improve survival. 
4.2.3 Scattershot achieves better performance in single drug prediction than previous methods 
We compared Scattershot to the method described in [66], which was the method most similar to 
Scattershot where it attempts to predict the same physician-coded drug response. Using the same 
response variables, the method in [66] built 4 models corresponding to expression, miRNA, copy 
number, and methylation for Paclitaxel in BRCA (no other BRCA-specific drugs were reported 
in that work), and reported that their best model was the miRNA model, which had a mean AUC 
performance of 67.3%. In contrast, Scattershot’s average Paclitaxel AUC performance is 81.8%. 
[66] also modeled the drug response for Carboplatin and Cisplatin with respect to the Pan-Cancer
analysis. Scattershot’s performance respect to Cisplatin AUC is 90.9%, and Scattershot’s 
performance with respect to Carboplatin AUC is 81.2%. In contrast, the strongest Cisplatin 
model in [66] was miRNA with an AUC 68.4% and the mRNA expression model of Cisplatin 
had an AUC of 62.6%. The best Carboplatin model in [66] was expression with an AUC of 
58.0%. These performance results suggest that Scattershot provides a framework that can better 
predict the drug response of single drugs. 
Three potential reasons Scattershot shows stronger performance than previous methods. 1) 
Scattershot identifies a data integration step that allows for the integration of data from multiple 
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sources, whereas the model presented in [66] only allows for one type of genomic data. 2) 
Scattershot’s feature selection step includes an initial cutoff that selects for significant cancer 
genes. 3) Scattershot’s inclusion of pathway features, and drug target features present add crucial 
clinically significant predictive features. 
Scattershot is able to incorporate multiple data types (binary variables, continuous variables, 
whole numbers, and integers), using the non-parametric Random Forest classifier which can 
incorporate multiple types input data to be present in the model without requiring normalization 
steps which result in information loss [160]. To explore the impact of data-integration, we ran 
Scattershot using one type of data only (expression-only model, copy number-only model, and 
mutation-only model) to predict drug response. For Paclitaxel in BRCA, the best model 
performance was gene expression with an AUC of 70.0%, lower than the fully-integrated model 
of AUC 81.8%. For Pan-Cancer Cisplatin, the best model performance was the mutation model, 
with an AUC of 75.2%, lower than the fully-integrated Scattershot model of 90.9%. For Pan 
Cancer Carboplatin, the best model performance was the expression model, with an AUC of 
61.9%, lower than the fully-integrated Scattershot model of 82.0%. 
We then examined the impact of Scattershot’s initial feature selection step. Unlike the previous 
method, Scattershot’s feature selection includes an initial cutoff of functional cancer genes from 
three sources: 1) known drivers found by the Cancer Gene Census [101], 2) drivers that have 
pathway impact from DawnRank [67], and 3) drivers that are associated with functional events 
in cancer [58]. This criteria leads to a feature space of 65 expression features, 76 copy number 
features, and 76 mutation features. The smaller feature space reduces the chances of overfitting 
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and prevents the model from selecting genomic features that provide little or no functional 
impact. To quantify the impact of this initial feature selection, we ran Scattershot without the 
initial feature elimination step and compared our results to the full Scattershot model. For 
Paclitaxel in BRCA, no feature selection yielded an AUC of 70.7%, higher than the model in 
[66] which had an AUC 67.3% but lower than the fully-integrated model of AUC 81.8%. For
Cisplatin in the Pan-Cancer analysis, no feature selection yielded an AUC of 81.4%, lower than 
the fully-integrated Scattershot model of 90.9%. For Pan-Cancer Carboplatin, no feature 
selection yielded an AUC of 52.1%, lower than the fully-integrated Scattershot model of 82.0%. 
Lastly, we examined the impact of pathway and drug target features in the model. The Paclitaxel 
model for BRCA, for example, consists of several features from drug targets and pathway 
features. This model consists of 10 features, and three of those features are pathway features: 
Cell Cycle Control (the most important feature), Receptor Tyrosine Kinase (RTK) signaling and 
Folate Transport. Additional two features are the PTEN and KRAS drug target. Mechanistically, 
these new features are quite important in Paclitaxel response. Paclitaxel mainly serves to enhance 
the polymerization of tubulin to stable microtubules, which are required to pass the G2/M phase 
of mitosis [161]. This explains why the Cell Cycle Control pathway variable is the single-most 
important predictor of Paclitaxel response. Receptor tyrosine kinases are cell surface receptors 
polypeptide growth factors, cytokines, and hormones that are key regulators in many cell 
processes. Paclitaxel and Trastuzumab (Herceptin) target RTK and are associated with stronger 
drug response [162]. Folic acid targets cell membranes and enhances endocytosis of 
nanoparticles, which facilitates the uptake of Paclitaxel to cancer cells, increasing its 
bioavailability [163] [164]. PTEN is a phosphatase and tensin homolog that plays a major role in 
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cell cycle progression and proliferation [165], and the PTEN signaling pathway has been linked 
to reversing chemoresistance to paclitaxel in p53 mutated cancer cells [166]. KRAS is a GTPase 
and is an early player in many signal transduction pathways [167], and Paclitaxel has been 
involved as a chemotherapeutic agent in KRAS mutated cell lines to improve drug response 
[168].  
4.2.4 Scattershot can accurately predict drug in pairwise recommendation mode 
We next ran Scattershot in pairwise recommendation mode to provide a ranked list of drugs 
using the results of the pairwise preference classifiers. As with the single drug classifier in SDM, 
we studied any drug that was prescribed in at least 5% of the patients to keep the n samples 
larger than the p features. This resulted in 11 eligible breast cancer drugs to rank and 22 eligible 
Pan-Cancer drugs to rank. Unlike the single drug mode, we were only concerned with whether a 
drug was prescribed, not whether the drug had a disease state or response outcome (see 
Methods). This was done in part to increase the number of drugs to rank to provide meaningful 
ranking results, in part because the vast majority (68%) of the prescribed patients exhibit a 
positive response, and in part to simplify the problem to keep the pairwise classifier a binary 
classifier for the rank aggregation method. The goal of each pairwise drug classifier is to 
determine whether or not a test patient would prefer one of the two drugs based on the patient’s 
genomic profiles. 
The results of the pairwise preference classifiers for breast cancer are shown in Figure 15. Figure 
3A shows the AUC evaluation and Figure 15B displays the kappa statistic for each pairwise 
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preference classifier. In breast cancer, we evaluated all but 3 of the potential 55 pairwise drug 
classifiers. We excluded Cyclophosphamide-Trastuzumab, Cyclophosphamide-Epirubicin, and 
Cyclophosphamide-Fluorouracil from the study due to severe class imbalance, where almost all 
(>99%) or none of the patients that were treated with Trastuzumab, Epirubicin, or Fluorouracil 
were also treated with Cyclophosphamide. 
For breast cancer, the average pairwise AUC is 82.8% with an average accuracy of 84.3%. Only 
one pairwise response, Epirubicin vs. Doxorubicin, out of 52 did not have a significant AUC 
when comparing with the model with a 0.5 AUC baseline. The average kappa statistic is 0.381. 
Looking at the kappa statistic, 10 of the 52 classifiers had a “slight” kappa score of 0-0.2, 20 of 
the 52 classifiers had a kappa score of 0.21-0.4, 11 of the 52 classifiers had a kappa score of 0.41 
to 0.6, and 11 of the 52 classifiers had a kappa score of 0.61 or higher. The distribution of kappa 
scores indicates that while the performance of the classifiers in general are not due to chance. 
However, the association is not very strong in many cases. One explanation for low kappa scores 
in some classifiers and high kappa scores in others may be related to drug mechanisms. 
Anastrozole, Exemestane, and Letrozole are all aromatase inhibitors with very similar 
mechanisms in estrogen receptor positive BRCA [169]. Due to drug response similarity, 
Scattershot has difficulty in comparing these drugs which explains why the kappa value of 
Anastrozole performs worst when paired with Exemestane and Letrozole, exhibiting a kappa of 
0.06 and 0.22.  
With regards to the Pan-Cancer analysis, the AUC results are higher than the breast cancer 
predictors with an AUC of 93.6%, and the kappa statistic is 0.765, and only 19 out of 209 
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classifiers returned a kappa of less than 0.2. This indicates that the overall classifiers for Pan-
Cancer analysis is very strong and that the vast majority of classifiers’ performance is not by 
chance. The kappa score for the pairwise classifier is substantially higher than they are for the 
breast cancer data meaning that the performance of Pan-Cancer classifiers is much less likely to 
be due to chance than in breast cancer. There are several differences in the data that are potential 
sources of this discrepancy. One reason is the larger n. The average preference classifier in Pan-
Cancer contains 2.3 times as many samples as the average preference classifier in breast cancer. 
Patients across multiple types of cancer have more distinguishable genomic features than patients 
within only one type of cancer. Cancer mechanisms vary from cancer to cancer, and some 
chemotherapeutic drugs are cancer-specific. An example of this is Bleomycin in Testicular 
Cancer (TGCT). Bleomycin is heavily prescribed in TGCT. 53 out of 162 TGCT patients, but it 
is not prescribed in patients in any other cancer. 
We next looked at the feature selection process for each of the subtypes in breast cancer. Figure 
15C highlights the most commonly selected features for each source of data with respect to the 
pairwise preference classifier. Selected features in Figure 15C represent the most commonly 
selected features when building a pairwise preference classifiers regarding the drug. With 
regards to expression data, the most selected feature is GATA3, which was heavily selected in the 
models of every drug, and EGFR and ERBB2, which are important features in 10/11 drug 
models. These three genes are known to be highly predictive of breast cancer subtypes, which 
are often used to prescribe drugs GATA3 along with BRCA1 is involved in pathogenesis of basal 
and triple negative breast cancer [170]. EGFR and ERBB2 are well-known for their driving 
potential in Her2 breast cancer [171]. For copy number analysis, PIK3R1 is the most selected 
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feature in breast cancer. PIK3R1 is selected in 8/11 drug models. PIK3R1 activated in response 
to activations in tyrosine kinases such as EGFR, VEGFR2, and ERBB2, and its involvement in 
multiple cancer pathways make it an ideal marker for predicting drug response [172]. BRCA2 is 
the most important mutation feature in the pairwise preference classifiers. BRCA2 is selected in 
10/11 drug models. The BRCA2 mutation, is a well-known hereditary mutation is involved in 
DNA repair mechanisms [173]. BRCA2-induced cancers are more likely to be ER+ and less 
likely to be Her2, and therefore, it is a strong treatment marker for ER+ prescribing drugs [174]. 
Pairwise classifiers involving Epirubicin and Docetaxel rely heavily on drug target features. 
Epirubicin-based classifiers use 80% of the available drug target features and Docetaxel-based 
features use 67% of the available drug target features. Both Epirubicin and Docetaxel have very 
similar drug target with common features such as ABCC6, NAT2, XRCC3, PRDX2, PLD2, 
SLCR10A2, TUBB, and NR112. Docetaxel and Epirubicin are often co-prescribed with targeted 
chemotherapy to improve drug response [175]. Some features such as multi-drug resistance 
proteins such as ABCC6 are associated with resistance to Docetaxel and Epirubicin treatment 
[176]. Pathway features may be quite drug specific, but many of the pathway features selected by 
our model agree with the current literature in breast cancer treatments. For example, 5-
Fluorouracil and Epirubicin are associated with telomerase length, and these two drugs have the 
telomere maintenance pathway as an important select breast cancer pathway [177]. In addition to 
genomic data and drug target-driver gene interaction, there are also important clinical features in 
breast cancer predictors, including ER status and Triple Negative status. This agrees with prior 
knowledge as the ER status or the lack thereof is often the most important current manual 
decision-making steps in breast cancer drug prescription as drugs [155]. 
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4.2.5 Scattershot in pairwise recommendation mode rankings are well associated with the 
prescribed drugs 
 
After building the pairwise response matrix, we used the FAS-Pivot algorithm to rank aggregate 
the pairwise comparisons and output a ranked list of drugs for each patient by relevance (see 
Methods). To evaluate the rankings, we compared the ranked list of drugs for each patient to the 
drugs that were actually prescribed to the patient by the health care provider. We used the 
precision @ k score to test the performance. The precision @ k score measures the precision, the 
percentage of drugs that were prescribed vs. all Scattershot proposed drugs at rank k [178]. 
Figure 16A illustrates the precision @ k score for each breast cancer drug. The precision @ 1 for 
Scattershot is 73.1% and the precision @ 2 is 56.6%. This means that for all patients, 
Scattershot’s top recommended drug was actually prescribed to the patient over 73% of the time, 
which indicates that Scattershot is able to reproduce a substantial number of physician 
recommendations in cancer. Scattershot’s second choice was prescribed over 56% of the time. 
The precision curve decreases with k, meaning that predictions ranked low are unlikely to be 
actually prescribed.  
 
To confirm that Scattershot recommends prescribed drugs higher than it does drugs that were not 
prescribed, we compared the distribution of the rankings for each drug when it was prescribed 
with the distribution of the rankings of the drugs when they were not prescribed (Figure 16B). A 
Mann Whitney Rank-Sum test showed that the rank difference between the Scattershot rank 
when the drug was prescribed compared to when it was not was statistically significant. The p-
value for each breast drug test was less than 0.05 for all 11 Scattershot breast cancer drugs, 
	 91	
meaning that Scattershot rankings for each drug were higher when the drug was actually 
prescribed. Similar results were found with the Pan-Cancer analysis, with a Mann Whitney 
Rank-Sum test showing that the rank difference was statistically significant for all 22 drugs 
(p<0.05).  
 
In breast cancer, the largest difference between Scattershot rankings is in Trastuzumab, or 
Herceptin. Scattershot’s rankings for Trastuzumab in patients where Trastuzumab was prescribed 
was 2.0 (See Figure 16B) while the median ranking for Trastuzumab where Trastuzumab was 
not prescribed was 11.0. Trastuzumab is often prescribed in aggressive Her2 BRCA patients, 
targeting growth factors such as ERBB2 and ERBB3, activating the PIK3 apoptosis pathways, 
and contributing to inhibiting cancer angiogenesis [179]. We looked at the features of the 
Trastuzumab pairwise classifiers and found that the most commonly selected features include 
ERBB2 and ERBB3 expression, copy number, and mutation features, PIK3R1 copy number, the 
Her2 clinical subtype, and the Angiogenesis pathways. Each of these features is a hallmark 
property in Trastuzumab response which may largely explain the reason the Trastuzumab 
ranking is so reliable. 
 
4.2.6 A cluster of Scattershot rankings reveals subtypes that are consistent with known breast 
cancer subtypes 
 
We further visualized the Scattershot personalized drug rankings by clustering the breast cancer 
patients based on the predicted drug rankings using hierarchical clustering with Ward’s linkage 
over the Spearman’s footrule distance. This resulted in five clusters from Scattershot 
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recommendations. We compared the breast cancer clusters based on Scattershot rankings to that 
of established cancer subtypes such as the ER/PR/Her2 [39] subtype classification as well as the 
commonly accepted PAM50 gene expression subtypes of Basal, Her2, Luminal A, Luminal B, 
and Normal-like [42] (see Figure 16C). We found that the Scattershot subtypes correspond very 
closely to each clinical subtype as well as each PAM50 subtype. A chi-square test for association 
was performed to determine the significance of the clusters, and a significant association was 
found between Scattershot drug recommendations subtypes with both the ER/PR/Her2 subtype 
(p-value < 2e-16 for each marker) and PAM50 subtypes (p-value < 2e-16). We found 5 subtypes 
in breast cancer based on drug prescription that were strongly associated both the clinical and 
gene expression subtypes. Three of the clusters (named Clusters 1, 3 and 5 in Figure 16C) are 
related to ER+ and PR+ breast cancer and the Luminal A and Luminal B PAM50 subtype (Chi-
square association test p <2e-16). Another cluster (Cluster 2) is related to the Her2+ subtype and 
the PAM50 Her2 subtype (Chi-square association test p <2e-16). The last cluster (cluster 4) is 
related to triple negative breast cancer and the PAM50 Basal subtype (Chi-square association test 
p <2e-16). 
 
We then compared the drugs that are associated with each cluster, using a Mann-Whitney Rank-
Sum test to compare the rankings of each drug within the cluster to those outside the cluster to 
determine if there is a significant association between the drug and the cluster. We used a 
Bonferroni correction for multiple testing. The ranking of Trastuzumab, which is associated 
strongly with the Her2 subtype, is strongly associated with high ranks in cluster 2 which 
corresponds to many Her2 patients (p <2e-16) and is also associated with low ranks in clusters 1, 
3, and 4.  Aromatase inhibitors in Anastrozole and Letrozole as well as anthracycline drugs in 
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Epirubicin and Doxorubicin are significantly associated with Cluster 1, a Luminal A and B and 
ER/PR+ subtype. Clusters 2 and 5 are other Luminal A and B and ER/PR+, however, and while 
most of the Cluster 1 drugs are still significant in clusters 3 and 5, the defining feature separating 
Clusters 3 and 5 from Cluster 1 is Tamoxifen, which is not significantly associated in Cluster 1, 
but is associated in Cluster 3 (p=1.68e-6) and cluster 5 (p=8.33e-5). Although Tamoxifen acts 
targeting the ER receptor, its mechanism is different from other ER drugs in that it causes a 
change in the folding of the steroid binding domain that prevents gene activation [180]. The 
drugs that define clusters 3 and 5 is Docetaxel which is not significant in Cluster 3, but 
significant in Cluster 5 (p = 1.63e-13). Docetaxel has been shown to effectively treat ER+ breast 
cancer patients, but the efficacy varies due to the level of ER expression [181]. 
 
The most interesting conclusions from Figure 16C come from Scattershot’s recommendations for 
Triple Negative Breast Cancer. Triple Negative Breast Cancer are defined by the lack of ER, PR, 
and Her2 receptors, and they are known for their low survival rates due to the lack of targeted 
therapies available [182][40]. In Triple Negative Breast Cancer, Scattershot tends to rank the 
drugs Cyclophosphamide, Fluorouracil, Epirubicin, and Doxorubicin high with statistical 
significance. Evidently, this corresponds to literature studies which show that both CEF 
(Cyclophosphamide, Epirubicin, Fluorouracil) and CDF (Cyclophosphamide, Doxorubicin, 
Fluorouracil) chemotherapies outperform traditional chemotherapy regimens for TNBC patients 
[183]. Triple Negative Breast Cancer patients are shown to be sensitive to anthracyclines such as 
Epirubicin and other DNA destabilization agents to a degraded DNA repair cascade in TNBC 
[184]. This result further demonstrates that the Scattershot clusters can be used to stratify breast 
cancer patients to well defined drug response subtypes. Therefore, Scattershot may be a useful 
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tool which could help physicians select a treatment by taking into account integrated genomic, 
drug target, and clinical outcome, complementing current strategies of identifying clinically 
relevant subtypes. 
4.3 Methods 
Scattershot operates under one of two modes: 1) single drug mode (SDM) and 2) pairwise 
recommendation mode (PRM). Single drug mode uses a classifier to predict the clinical response 
to a single drug in a group of test patients. Pairwise recommendation mode is a multilabel 
classification method (a method that predicts multiple responses simultaneously) that provides a 
ranked list of drugs in a test patient ordered from most to least likely to respond. We use 
multilabel problem transformation techniques [185] to transform a comparison of many drugs to 
a comparison of any two drugs in a binary classifier in which test patients are classified a 
“preference” between the two drug. The preferences binary classifiers are then rank-aggregated 
using the pairwise rank aggregation FAS-Pivot algorithm to determine a final rank (see the 
multilabel Rank Prioritization Section). The classifiers in both modes are based on Random 
Forest incorporating a wide array of integrated features from a multitude of data sources 
including molecular signature data in expression, mutation, and copy number information 
combined with drug target, pathway interaction, and clinical data (see Figure 13). 
4.3.1 Data Collection 
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All genomic features and drug response data were downloaded originally from TCGA [152]. For 
common genomic features, we obtained preprocessed and curated data from cBioPortal [127]. 
We used the genomic information including: mRNA expression (median z-score), copy number 
information (based on GISTIC [128]), and mutation information.  Although methylation 
information was shown by [58] to improve drug prediction models on GDSC cell lines, we 
excluded methylation data in this work due to a large number of missing values in breast cancer 
samples (29%) and an absence of reliable methylation HumanMethylation27 BeadChip 
information in ovarian cancer. We obtained genomic information from 15 cancers with a 
substantial number of patients with both genomic feature information and drug information: 
BLCA (bladder cancer), BRCA (breast cancer), CESC (cervical cancer), GBM (glioblastoma), 
HNSC (head and neck squamous cell), KIRC (kidney cancer), LGG (low grade glioma), LUAD 
(lung adenocarcinoma), LUSC (lung squamous cell carcinoma), OV (ovarian cancer), PAAD 
(pancreatic cancer), PRAD (prostate cancer), TGCT (testicular cancer), UCS (uterine 
carcinoma). 
Drug response information was also obtained from TCGA through the Broad institute [186] and 
the TCGABiolinks R package [187]. Drug response was recorded in the TCGA as one of five 
outcomes. The five outcomes, ordered from best to worse, are as stated: “Complete Response”, 
“Partial Response”, “Stable Disease”, “Radiographically Progressive Disease”, and “Clinically 
Progressive Disease”. The names of the recorded drugs and treatments in TCGA, however, are 
not standardized and require curation due to the use of formatting differences and the use of 
differing names for the same drug (e.g., Generic and Trade Name) [65]. The paper [66] provides 
a dictionary which translates all TCGA prescriptions to a standardized DrugBank ID [188] for all 
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treatments that were prescribed in a patient that yielded a drug response. We added curations to 
original dictionary to include prescriptions that yielded a missing or unknown responses using 
the same methodology from [66], standardizing prescription names to the corresponding 
DrugBank ID [188]. 
 
We included missing values in the pairwise recommendation mode analysis for several reasons. 
First, the vast majority of drug prescriptions in TCGA (68%) have no corresponding drug 
response. This can contribute to the small n large p problem where the number of features is 
much greater than the number of samples to train [189], or it can severely limit the number of 
drugs that we can apply to Scattershot, reducing the scope of the problem. Second, the mere 
prescription of the drug in an actual clinical setting implies that the physician believes that the 
drug will elicit a positive response in the patient. A majority of patients treated with any drug 
will respond favorably. 63.9% of patients prescribed with a certain drug had a “Complete 
Response”, 70.4% patients had a “Complete” or “Partial” response, and 83.0% of the patients 
had a “Stable Disease” response or higher. Therefore, we included all drug prescription 
information with missing and unknown values in order to increase the power of our classifiers. 
 
For drug target specific features, we gathered gene network and pathway information with 
respect to drug target and mutations. We used the gene network of 8726 genes from [67], which 
is a network combined with curated KEGG data [190] as well as non-curated interactions from 
[191]. We used 13 cancer pathways defined as “General” cancer pathways from cBioPortal 
[127]. Drug targets were obtained using the Drug Gene Interaction Database (DGIdb) [147]. 
Although, its compendium is not complete, the DGIdb compendium is one of the most extensive 
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databases to characterize drug interactions with the genome, integrating data from multiple well 
known databases. For mutation information, we focused only on mutations in known driver 
genes defined by the Cancer Gene Census [101]. All data was accessed on 7/9/2016. All in all, 
1508 patients across 15 cancers were analyzed. Of that, the cancer type with the drug 
information was breast cancer, with 647 patients. Because breast cancer is the cancer with the 
most prescription information by far, we did two analyses on drug response: one with only breast 
cancer patients and the other Pan-Cancer analysis with all 15 cancers. With the dataset, we made 
a training and test dataset with the training dataset consisting of 90% of the data and the test 
dataset consisting of the remaining 10%. Ten training datasets were created this way for a 10-
fold cross-validation. 
 
4.3.2 Binary Classification 
 
Both single drug and pairwise recommendation modes use binary classification at the heart of 
their method. In single drug mode, the binary response variable is 0 if the treatment elicits no 
drug response and 1 if the treatment does elicit a drug response. We define a drug response as a 
recorded outcome corresponding to a response state: either “Complete Response” or “Partial 
Response”. We define no response as a recorded outcome corresponding to a disease state: either 
“Stable Disease”, “Clinically Progressively Disease”, or “Radiographic Progressive Disease”. In 
pairwise recommendation mode, we created a binary classifier for each pairwise drug 
comparison using a training dataset of 90% of the data and a testing dataset of 10% of the dataset 
with 10-fold cross validation. Each pairwise binary classifier represents a preference of one of 
two drugs. If both drugs are prescribed in the same patient, the preference goes to the drug that 
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elicits the stronger response, and the patient is removed from the classifier if both drugs elicit the 
same response.    
 
Algorithm 4.1 listed below explains the building of the binary classifier. The first set of 
Algorithm 4.1 is to calculate process the features used in the model. We initially process the 
genomic features F, the distance features T, and the pathway features S, separately and merge 
them together to make the combined feature space for the model. We then implemented a 
Random Forest classifier with recursive feature elimination to predict the final outcome. The 
feature elimination step involves building the model with all the features, eliminating the features 
that provide the least amount of information according the Random Forest GINI index, and 
rerunning the model again until the model performance no longer performs better than the 
previous model. In single drug mode, it is the physician-coded drug response, and in pairwise 
recommendation mode, it is an indicator of which drug is most likely to be prescribed. 
 
We selected Random Forest as the binary classification model for three main reasons. 1) 
Random Forests have few parameters to train. 2) Random Forests do not require normalization 
3) Random Forests are more robust (though not immune) to small n large p problems. The only 
parameters that Random Forests are required to train are the number of features for each decision 
tree and the number of trees that make up the forest [192]. This is less than similarly performing 
methods such as SVM which require more parameters for any given kernel. Random Forests also 
do not require normalized data. Random Forests are better able to handle small n large p because 
it is an ensemble method aggregating results of multiple models (Random Trees) with a small 
number of features [193]. To evaluate our method, we ran Random Forest with 10-fold cross 
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validation training with 10, 50, 100, 500, 1000, and 5000 and we found that 5000 trees yielded 
the highest performance. We trained 1 to 10 features per tree and we selected the parameter on a 
per-model basis based on the 10-fold CV result, and we reported the median result from our 
classifier. We used the R package RandomForest to analyze our model. 
 
The genomic features F used in each binary classifier fall under one of three groups: (i) genomic 
features, (ii) drug-specific pathway target features, and (iii) clinical features. The genomic 
features include information from mutation, expression, and copy number information. Because 
the number of potential features from this data is large (~33,000) and can contribute to the small 
n large p problem, we limited genomic features to features that satisfy each of the following 
criteria: (i) genomic features with known tumorigenic properties, or driver genes; (ii) genomic 
features with network impact; and (iii) genomic features that have been previously identified as 
clinically relevant in cell line studies. We used the 580 driver genes in the Cancer Gene Census 
(CGC) [101]. Highly impactful genes were calculated by DawnRank [67], selecting a 
corresponding number of highly-ranked, significant, impactful genes in the cancer pathway. We 
used the cell line study [58] to detect Cancer Functional Events (CFEs), which are features from 
cell line data associated with drug response. Using the intersect of all three of the following 
criteria, we used 65 expression features, 76 copy number features, and 76 mutation features. For 
drugs that had DGIdb drug targets outside these 76 genes, the expression, copy number, and 
mutation features of those target genes were also included in the model. For breast cancer, we 
also used basic clinical information as well. We used patient information such as age as well as 
specific tumor staging (T, M, N information) [194] and subtype and tissue type information 
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[195]. The subtypes used for the breast cancer analysis are the clinical subtype (ER, PR, Her2) 
and not the PAM50 subtype. 
 
In addition to basic genomic and clinical features, we also sought to include information that 
quantifies the interaction between the drug’s targets with the patient’s driver genes. This is 
matrix T in algorithm 4.1. The drug target / driver gene interaction has been hypothesized to be 
predictive of drug response. Studies such as [63] operated under the paradigm that drugs that 
directly target a driver gene or target a gene that interacts with the driver should be candidates 
for targeted therapy. The authors used the drug target / driver gene interaction to assign targeted 
therapy to patients based on how close the drug target was to the patient’s driver genes. We also 
calculated the drug target / driver gene interaction in our model. For each drug target, we 
calculated the Dijkstra’s shortest path distance [196] for the drug target corresponding to the 
patient’s nearest predicted driver mutation (shortest Dijkstra’s path distance). This outputs a 
distance feature for each drug target. In pairwise recommendation mode, we consider two drugs 
at a time, so we used the drug targets of both drugs as features. For each drug, we also calculated 
the absolute minimum distance between all drug targets and all driver genes. The absolute 
minimum distance represents the smallest possible interaction distance between any drug target 
and any driver gene, which indicates the overall most likely mechanism in which a cancer drug 
would act on the patient. 
______________________________________________________________________________ 
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______________________________________________________________________________ 
(Algorithm 4.1) 
 
To complement the drug target-driver gene interaction, we further complemented our model with 
pathway information. This is matrix S in Algorithm 4.2. Driver genes affect tumorigenesis by 
acting on cancer pathways which act in tandem to produce a phenotypic effect. Important 
pathway features such as PIKC3A/AKT’s effect on apoptosis have been shown to be clinically 
significant features when perturbed in cell line models, which showed that drug target and driver 
gene interacting within the same pathway have an impact on predicting drug response [58]. We 
captured this type of interaction by mapping the distance of a driver to a specific cancer pathway 
by calculating the shortest path distance between the any driver gene with any gene in the 
pathway. Values closer to 0 indicate that the pathway interacts more closely with a patient’s 
drivers while values equal to 0 indicate that the pathway is directly perturbed in a patient. We 
used the R package igraph to calculate the pathway interaction values [197]. 
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The features in the model F, T, and S were then merged to form the feature space, which range 
from 217 to 265 total features. Although this feature space is much smaller than the potential 
30,000 features possible in our model, the limited availability of treatment information in many 
drugs still leaves us prone to overfitting from the small n large p problem. To rectify this, we 
used Recursive Feature Elimination (RFE). RFE eliminates redundant or irrelevant features to 
yield the most precise set of genes with the greatest predictive accuracy, and it has also been 
shown to have high predictive power in predicting cell line response [198]. RFE works by 
building a full model and calculating its performance, then rank ordering each variable by its 
importance, and then eliminating the least important features from the model and reevaluating 
the method to determine if there is an improvement in performance. The importance for our RFE 
was the Gini coefficient, the entropy calculation of Random Forest classifiers. The RFE process 
is repeated until there is no improvement in the model from eliminating features. The RFE step 
in our model was built using the R package, Caret [199]. One instance of Scattershot takes 1 
hour and 15 minutes on an 8 GB ram personal computer. 
 
4.3.3 Pairwise Rank Prioritization 
 
For Scattershot to run in single drug mode, only the binary classification step is needed. 
However, the drug prioritization step of pairwise recommendation mode requires an additional 
step to create the ranked list for drug prioritization. Algorithm 4.2 below describes the 
Scattershot approach. Comparing the results of many related labels (in this case, drugs in vector 
d), is a challenging machine learning problem because the labels do not act independently, and a 
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multilabel framework is designed to better handle inter-dependencies and interactions of the 
labels (drugs in this case) [69]. 
______________________________________________________________________________
 
______________________________________________________________________________ 
(Algorithm 4.2) 
We use binary problem transformation to convert the multi-label problem into single label 
problems. We compare two labels at a time for every combination of labels in one-vs-one 
comparison over the feature space F described in the previous section. This differs from the 
traditional one-vs-all problem formulation in which a classifier is built for each drugs in that in 
that it maps drug interactions and dependencies where one-vs-all methods cannot. One-vs-all 
problem formulation is the default model used most current methods in predicting drug response 
in cell line data, including the most recent [58].  
 
The result of each classifier indicates whether or not a test patient is more similar to patients 
prescribed with one of two drugs, resulting in a “preference” of one of these two drugs. The 
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advantage of using problem transformation is that we account for any potential interactions and 
interdependencies which may confound our data while at the same time simplifying the problem 
to binary, single-label, preference. The pairwise preferences, calculated as the median result from 
the 10-fold CV, are used to build a pairwise comparison matrix, P. P is unique for every patient 
in the test set. When comparing k drugs, P, is a k x k matrix holding the result of the drug 
preferences (results of the binary classifiers) for the test patient in which Pi,j is 1 if the patient is 
more likely to prefer drug i and 0 if the patient is more likely to prefer drug j. When i =j, no 
value is given in the matrix. A pairwise rank aggregation step is then done on P to obtain the 
final result. Scattershot’s model follows that of pairwise classification described in [200], which 
showed that pairwise, one-vs-one classification can be utilized to output promising experimental 
results compared to traditional one-vs-all methods. 
 
Algorithm 4.3 listed below describes the FAS-Pivot pairwise rank aggregation algorithm to 
determine the final drug rankings, which is a special case of the FAS-Tournament sports 
algorithm designed to rank sports teams in the wake of a large amount of inconsistent 
information [201]. FAS-Pivot provides a globally consistent rank solution when there is potential 
for large number of disagreements and inconsistent information in the pairwise ranking matrix P. 
FAS-Pivot is especially important for drug prediction in patient samples because the dataset 
itself is subject to many confounding factors beyond the scope of genomic data that may lead to 
inconsistent information. Confounding factors include patient demographics, patient medical 
histories, and environmental information which are not well recorded and difficult to adjust 
[202]. FAS-Pivot works by first selecting a random drug pivot q among all drugs in P. 
Afterwards, it splits each remaining drug into one of two vectors vL and vR. vL contains all drugs 
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preferred over the pivot and vR contains all drugs not preferred over the pivot. A pairwise matrix 
P[vL,vL] consisting of only drugs prefered over the pivot and then FAS-Pivot is run recursively 
with the input  P[vL,vL]. The results are appended to the left of the pivot.  A pairwise matrix 
P[vR,vR] is also made for drugs not preferred over the pivot, and then FAS-Pivot is run 
recursively with the input  P[vR,vR], and the results are appended to the right of the pivot. The 
algorithm runs the input of FAS-Pivot is a 1 x 1 matrix in which only the pivot is returned or a 0 
x 0 matrix in which nothing is returned. 
____________________________________________________________________________ 
 
______________________________________________________________________________ 
(Algorithm 4.3) 
FAS-Pivot has a distinct advantage over traditional rank-prioritization methods such as 
Condorcet Voting in that it will output a ranked list in all circumstances while Condorcet Voting 
may be trapped in cyclical ranks [203]. Cyclical ranks are avoided by FAS-Pivot because FAS-
Pivot forces a rank by comparing all drugs to a single pivot. Missing values in the pairwise rank 
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aggregation matrix were imputed by allowing downstream calls to rank the drug and applying 
rank-balancing as seen in [201] by using Spearman’s footrule distance to obtain a consensus rank 
over 100 FAS-Pivot calls. We implemented FAS-Pivot in R and used the R RankAggreg 
package for rank balancing via Spearman’s footrule distance [110]. 
 
4.4 Discussion 
 
The results of Scattershot highlight a method that can both predict the response of a single drug 
as well as rank-prioritize a list of drugs for any given test patient. Running Scattershot in Single 
Drug Mode found that Scattershot greatly outperforms previous methods in terms of predicting 
the response of the drug. Scattershot models several drugs such as Anastrozole and Tamoxifen 
using genomic markers that are indicative for survival. In Pairwise Recommendation Mode, we 
found that the pairwise classifiers predict the assigned drug with a high accuracy. The rank list of 
Scattershot recommendations indicate that the most recommended drugs are drugs that were 
actually prescribed with a high precision. BRCA subtypes based the Scattershot rankings are 
highly predictive of previously defined BRCA subtypes such as clinical subtypes and PAM50 
gene expression subtypes.  
 
The Scattershot method does have its limitations, and further work needs to be done to confirm 
and improve the results of Scattershot. One limitation of Scattershot lies within the quality of 
data in Scattershot. This extends to both the qualitative nature of the drug response information 
in the TCGA patient histories which are subject to subjectivity by physicians. Additionally, some 
of the input data may need to be examined further. One example of this lies in the drug target 
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information found in DGIdb. The database, while extensive is not complete, and it draws from 
drug target information from multiple sources. To ensure the highest quality in results with 
respect to drug target information, manual curation is a potential future step to fill in potential 
gaps of the non-curated drug target database.  
Another main difficulty in the classification step of Scattershot was the small number of samples 
for any given classifier. The small n may be one of the leading explanations to some of the low 
Cohen’s Kappa score in some classifiers. As more data is recorded, Scattershot may improve 
over time by more reliably predicting the response and prescription of more drugs. As more drug 
information becomes available in the future, we also plan to improve the Scattershot pairwise 
classifiers so that they simultaneously take into account prescription and the magnitude of 
response rather than a simple binary to determine drug prescription. 
Scattershot is a new computational method that can help clinicians prioritize potential drug 
treatments and predict the response of a certain drug to a patent. Researchers can utilize the 
Scattershot pipeline to select for important features that define the drug response for specific 
drugs. The pairwise classifier may also provide insight of drug-interactions as it directly 
compares the response of two drugs. Taken together, Scattershot shows strong promise in its 
application to predict drug response and to recommend drugs on a personalized basis. 
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FIGURES 
 
Figure 13: The workflow of Scattershot. It describes the steps necessary to run Scattershot in 
pairwise recommendation mode. In single drug mode, the drug response in the output so the 
method stops at the classification step. The lower portion of the figure illustrates the features and 
the feature types selected by Scattershot. 
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Figure 14: The performance evaluation of Scattershot run in single drug mode to measure drug 
response. (A) The ROC plots show the results of single drug mode Scattershot with breast cancer 
patients only in terms of Specificity (X axis, in reverse) and Sensitivity (Y-axis) for …. (B) The 
survival differences are shown for patients with predicted positive responses to the drug in 
question vs. predicted negative responses. The X axis represents survival time in days up to 5 
years and the Y axis represents the percentage of patients surviving. (C) The ROC plots show the 
results of single drug mode Scattershot with Pan-Cancer patients in terms of Specificity, the true 
negative rate compared to all negatives (X-axis, in reverse) and Sensitivity, the true positive rate 
compared to all positives (Y-axis). 
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Figure 15: A summary plot of the breast cancer performances of the pairwise binary relevance 
classifiers when Scattershot is run in pairwise recommendation mode (PRM). (A) The median 
AUC values from the 10-fold CV of each pairwise classifier are shown in the lower triangle and 
the corresponding color and size intensity are in the upper triangle. (B) The C value of each 
pairwise classifier are shown in the lower triangle and the corresponding color and size intensity 
are in the upper triangle. (C) We show the feature selection variables for each type of data. The 
X-axis represents the feature type and they Y-axis represents the drug. A value is colored if the 
feature was selected in at least 25% of the models involving the drug. 
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Figure 16: A summary plot of the recommendations in breast cancer after Scattershot’s Rank 
Aggregation step was performed on the pairwise binary relevance classifiers in pairwise 
recommendation mode. (A) We show the Precision @ k Score with the X-axis indicating the 
ranking and the Y axis indicating the Precision at that ranking. (B) We visualize the rank 
distribution of all 11 breast cancer drugs (X axis) ordered by prescription frequency, between all 
Scattershot ranks where the drug was actually prescribed (Blue-Green) and the ranking when not 
prescribed (red). The Y axis represents the final rank. Note that lower rankings indicate the top 
Scattershot recommendations while upper rankings indicate the worst Scattershot 
recommendations. (C) A clustering landscape of breast cancer patients (X axis) and drugs (Y-
axis) is shown. The intensity of purple signifies higher rank. The Spearman’s footrule 
Hierarchical Clustering is seen at the top followed by the k=5 split for Scattershot clusters. The 
bottom tracks indicate the clusters of other breast cancer subtypes in PAM50 and ER, PR, and 
Her2 markers. 
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CHAPTER 5: Conclusions 
 
5.1 Summary 
 
The process of bringing cancer treatment models from the lab bench to the patient bedside 
remains one of the daunting challenges in making personalized medicine a reality. This 
dissertation identifies several key aspects of this ordeal and proposes several new computational 
methods to overcome these challenges. First, our thesis identifies the drivers of cancer. We built 
the method DawnRank which integrates mutation data, gene expression, and network 
information to discover drivers in a personalized manner that is geared towards finding 
especially rare and novel drivers which may have been masked by previous methods. We further 
demonstrated the power of DawnRank by using it to identify driver subtypes in BRCA. 
DawnRank, coupled with Consensus Clustering found 5 novel subtypes in BRCA while defining 
driving chromosomal hotspots of copy number alterations in breast cancer, including 1q 
amplification, 8q amplification, 11q loss, and 16q loss. Three subtypes correlate highly with the 
Luminal A subtypes, one with Basal/Her2, and the final with LumB/Her2. Additionally, the 
subgroups correlate with known clinical markers such as the estrogen and progesterone receptors 
with the Luminal subtypes, TP53 mutation in the Basal/Her2 subtypes, and worsened overall 
survival in the Basal/Her2 subtype. DawnRank’s BRCA subtype analysis provides a proof-of-
concept which can be used to stratify patients into subgroups that can later be defined by 
potential personalized treatment. 
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We also addressed the concept of multiple drivers and the pathway-level impact involved in 
cancer progression. We described a novel method, termed C3, which has the potential to 
precisely and efficiently identify clusters of gene modules with mutually exclusive mutation 
patterns. The C3 algorithm uses large-scale cancer genomics datasets which are pre-processed to 
yield parameters governing novel constrained correlation clustering techniques. The optimization 
criteria used in clustering include patterns of mutual exclusivity of mutations, patient sample 
coverage, and network driver concentration. C3 improves over previous methods that use 
randomized with fixed cluster sizes approaches without the guarantee that multiple runs of the 
methods on the same data will produce compatible results for any cluster size. C3 was able to 
identify several potential driver pathways when applied to BRCA and GBM data that could 
guide new drug targets and new drug mechanisms. 
 
Finally, we presented a novel method that ties in the insights we obtained from molecular 
signature and pathway information to prescribe treatments to cancer patients. Scattershot’s 
comprehensive genomic, pathway, and clinical data to predict the drug response of a patient and 
make a ranked list of drug recommendations for any given patient in silico. We applied 
Scattershot to 647 breast cancer patients and a Pan-Cancer study of 1508 patients from the 
publicly available TCGA database. Scattershot’s integrated approach has outperformed previous 
methods in predicting drug response in actual patient samples, and its novel recommender has 
consistently ranked actual prescribed drugs highly in a large majority of patients.  We believe 
that Scattershot provides a framework which can be used to personalized treatment approaches in 
cancer. 
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5.2 Future Directions 
 
The conclusions from the chapters of the thesis pave the way for several potential future 
directions of our projects. In Chapter 2, one of the areas of interest lies in the construction of the 
gene network. We are also limited by the biased by the curated pathway used to evaluate the 
networks. The gene network is not complete, with many interactions incomplete. Additionally, 
the interactions between the genes themselves may change in a cancer genome. One future 
direction to model the interaction of the gene network is to utilize a dynamic network where the 
nodes and edges are specific to an individual cancer patient. Additionally, we would like to 
access the effect of the driver genes over time comparing pre-treatment and post-treatment 
samples) to determine if there are any changes in the driver function after treatment. We are also 
interested in looking at drivers that participate in the metastatic process. Metastases is the leading 
cause of cancer related deaths, and oftentimes a small percentage clone in the primary causes 
seeding of distant metastases. Thus, drivers identified in the primary may not be the main causes 
of metastasis or the genes that need to be targeted to halt metastatic progression. Future studies 
on large cohorts of matched primaries and metastases will soon answer these questions. In vitro 
and in vivo studies can also be used to confirm our findings. 
 
Several directions of future work are also present in Chapter 3. From a technical standpoint, 
several improvements can be made on determining the weights of the algorithm. Weights in C3 
were determined heuristically, using a brute force method to test C3 on multiple weighting 
parameters. This manner of selecting weights is less efficient and time consuming if optimal 
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weight parameters change in different cancer studies if the optimal weights for C3 vary from 
cancer to cancer. In the future, we plan on applying C3 to other data sets and other cancers to 
determine to determine whether the optimal weights for expression, coverage and mutual 
exclusivity vary within different biological context. Also, In vitro and in vivo studies can also be 
used to confirm our findings. 
 
Future work can also address limitations in Scattershot in Chapter 4. To a large amount of 
missing information, Scattershot’s drug response may be incomplete. This is especially true for 
many of the cancers outside of the 14 chosen in the Scattershot parameter selection. When more 
information from TCGA is made available, we will be able to update the results of Scattershot. 
Additionally, more scrutiny and curation can be made in the DGIdb derived drug target 
information. A manual curation of drug targets with like-mechanism drugs serving as a baseline 
may be useful in supplementing some potential incomplete information a generalized, non-
curated method like DGIdb provides from drug targets. Scattershot should be run in the future to 
create a more complete analysis of Pan-Cancer response once the TCGA data is updated. For this 
part of the analysis, in vitro cell line analysis may be used to confirm the findings of Scattershot.  
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